Received: 29 April 2021 | Revised: 6 July 2021 | Accepted: 7 October 2021

DOI: 10.1002/med.21863

REVIEW ARTICLE

Medicinal Research Reviews WILEY

Mechanism of activation and the rewired network: New drug design concepts

Ruth Nussinov[1,2] | Mingzhen Zhang[1] | Ryan Maloney[1] | Chung-Jung Tsai[1] | Bengi Ruken Yavuz[3] | Nurcan Tuncbag[3,4,5] | Hyunbum Jang[1]

[1]Computational Structural Biology Section, Frederick National Laboratory for Cancer Research in the Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, Maryland, USA

[2]Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

[3]Department of Health Informatics, Graduate School of Informatics, Middle East Technical University, Ankara, Turkey

[4]Department of Chemical and Biological Engineering, College of Engineering, Koc University, Istanbul, Turkey

[5]Koc University Research Center for Translational Medicine, School of Medicine, Koc University, Istanbul, Turkey

Correspondence
Ruth Nussinov, Computational Structural Biology Section, Frederick National Laboratory for Cancer Research in the Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD 21702, USA.
Email: NussinoR@mail.nih.gov

Funding information
National Cancer Institute, Grant/Award Number: HHSN261201500003I

Abstract

Precision oncology benefits from effective early phase drug discovery decisions. Recently, drugging *inactive* protein conformations has shown impressive successes, raising the cardinal questions of *which targets can profit and what are the principles of the active/inactive protein pharmacology*. Cancer driver mutations have been established to mimic the protein activation mechanism. We suggest that the decision whether to target an inactive (or active) conformation should largely rest on the protein mechanism of activation. We next discuss the recent identification of double (multiple) same-allele driver mutations and their impact on cell proliferation and suggest that like single driver mutations, double drivers also mimic the mechanism of activation. We further suggest that the structural perturbations of double (multiple) *in cis* mutations may reveal new surfaces/pockets for drug design. Finally, we underscore the preeminent role of the cellular network which is deregulated in cancer. Our structure-based review and outlook updates the traditional Mechanism of Action, informs decisions, and calls attention to the intrinsic activation mechanism of the target protein and the rewired

tumor-specific network, ushering innovative considerations in precision medicine.

KEYWORDS
cancer network, driver mutations, drug discovery, inhibitor, kinases, KRAS, K-Ras4B

1 | INTRODUCTION

Drug discovery has encountered expensive and daunting failures. At the same time, it has been notable for its innovation, inspiring successes, and promising advancements. Among these is first, the successful drugging of the *inactive* state of an unyielding protein, the "then-undruggable" KRas4B, by thwarting its mechanism of activation.[1,2] An a priori identification of those proteins whose *inactive* state is more likely to be susceptible to drugs than their *active* state is expected to be immensely valuable to drug discovery decisions.[3] A second advancement with therapeutic potential is the discovery of the co-occurrence of multiple cancer driver mutations on the same allele, that is, *in cis*.[4–7] Even though expected,[8] only recently it has been validated on cancer genomes and shown to promote more vigorous oncogenic signaling and higher sensitivity to inhibitors. This is particularly notable since the observation was on proteins (e.g., phosphatidylinositol 3-kinase α [PI3Kα]) lacking effective isoform-specific pharmacology.[9,10] This observation heightened optimism of more effective and safer next-generation drugs by reining in hitherto overlooked conformations. In a third advancement, a combined orthosteric plus allosteric drugs strategy targeting the same protein has shown promise in drug resistance (e.g., Bcr-Abl kinase drugged with imatinib or nilotinib and GNF-5 compound).[9,11,12] As we discuss below, such promising observations are all structure-based and their theoretical basis can be straightforwardly understood. However, challenges lie in their practical implementations.

Here, we consider these drug discovery landscapes and review the concepts and literature along these lines. This leads us to suggest that the activation mechanism at the structural level can help guide drug discovery decisions.[3] Why should the activation mechanism of the enzyme (or receptor) be considered in making drug discovery decisions? Cancer driver mutations work by mimicking the activation mechanism of the wild-type protein—except that they override its regulation.[13–15] There are multiple pioneering examples indicating such mimicry.[15–17] Drug discovery may similarly benefit from deliberating the protein activation mechanism undertaken by nature. As to the co-occurrence of double (multiple) cancer driver mutations *in cis* on the protein target,[4–6] protein conformational behavior suggests that the additive effect of the mutations is unlikely to alter the activation mechanism which would still mimic that of the wild-type protein.[18] However, the more potent signaling that the multiple mutations abet argues that significant differences in structural details are likely to emerge.[7,19] These might be harnessed to yield more specific, safer drugs. Finally, for the third, orthosteric plus allosteric combination, extensive molecular dynamics (MD) simulations can couple with experiments to identify the allosteric drug that can mitigate drug resistance to enable the orthosteric drug to block the active site, thus ligand binding.

Much has already been said about precision oncology and its treatment decisions. It has also been postulated that they largely rest on genomic testing, next-generation sequencing which along with additional clinical data can lead to effective pharmacology. The challenging dilemma of the interpretation of the patient's cancer genome landscape has been deliberated as well (e.g., Nussinov et al.[20] and Schwartzberg et al.[21]). The literature is rife with reviews of cancer development and progression, and drug resistance linked to these.[22–25] Here, we consider the innovative drug discovery landscapes noted above, review the concepts, and propose new principles. This review distinguishes itself by providing an innovative structure- and mechanism-based drug discovery outlook for drug discovery decisions.[26,27] We discuss drug discovery scenarios that are based on activation mechanisms, their

advantages and caveats, and some possible guidelines as to when and how to implement them, updating the traditional phenomenological Mechanism of Action (MOA). Especially, we underscore the importance of heeding the activation mechanism of the protein designed by nature and the preeminent role of the rewired cellular network in cancer.

2 | THE TRADITIONAL MOA CLASSIFICATION

Initiating from target identification, drug discovery involves a broad range of considerations and decisions.[27–33] Traditionally, they may include diverse combinatorial screening strategies. Some are aided by reporters, medicinal chemistry, and optimization of candidates to increase affinity and selectivity, efficacy or potency, toxicity, metabolic stability (half-life), and oral bioavailability. In recent years screening and optimization of approved drugs for repurposing has been especially prominent.[34–37] Drugs have been grouped based on their therapeutic use and dominant MOA, which can be complicated since drugs can have multiple mechanisms of action which can also be defined at multiple scales. The drug's MOA also includes the molecular targets to which it binds, such as an enzyme or receptor, whether it produces a change in the cell function, such as cell growth, and how it produces the effect on the specific target in the cell.[29,38] A drug class has been defined as a set of medications (or compounds) that have similar chemical structures thus a likely related mode of action, and/or used to treat the same disease. A pharmacologic class has been defined as a group of active moieties that share properties defined on the basis of MOA, Physiologic Effect, and Chemical Structure.[39]

Yet, standard structural classification, such as competitive (orthosteric, binding at the active/functional site) or noncompetitive (allosteric, binding away from the active/functional site), covalent, or noncovalent has not been included. The structural classification is not based on the molecular mechanism of activation, that is, whether the drugs target the *inactive* state of the enzyme or the *active* state. Diverse types of structural approaches, here compiled for oncogenic Ras as examples, are not there either.[2,40–64] Feature-related structural classification such as drugs blocking membrane anchorage through, for example, inhibition of farnesyl transferase (FTase) and translocation to the plasma membrane (e.g., tipifarnib, deltasonamide)[65–68] are missing as are drugs stabilizing or disrupting protein–protein interactions (e.g., dimerization, Ras-effector interactions)[69–72] and monobodies.[46,61,73] Driver mutations commonly mimic these mechanisms, promoting membrane attachment, as in the case of PI3K[7,74–79] or debilitating it, as in phosphatase and tensin homolog (PTEN) tumor suppressor[15] where they reduce membrane association, like K13E, S10N, G20E, L42R, and F90S, near the phosphatidylinositol-3,4-bisphosphate (PIP_2)-binding pocket.[15,80–84] Notably, not all structural mechanisms commonly adopted by driver mutations can be directly targeted by drugs. A case in point is relieving the autoinhibition, another frequent mutation strategy.[13,85–100] The significance of a molecular view of MOA as compared with a traditional phenomenological outlook is evidenced from refocusing the therapeutics from tissue- or cancer type-based, to cancer genomics and accurate protein structural data. The latter perspective has been adopted by precision medicine, altogether arguing for an update and modernization of the traditional MOA.

3 | PROTEIN STRUCTURE-BASED MOA DRUG CLASSIFICATION

We list major protein structure-based drug classes along with brief descriptions of some of their attributes. Among these, (i) orthosteric drugs are the oldest category.[101] These are competitive drugs designed to dock into the active, or functional site. Their advantages include knowledge of the active site. Since, however, active sites are conserved in protein families, orthosteric drugs are prone to eliciting side effects. Their affinity will also need to be significantly higher than that of the native ligand or cofactor with which they will need to compete. At the same time, the dosage cannot be too high due to side-effects from binding to homologous active sites. They work by blocking the active

site. Drug resistance mutations commonly work by modifying the active site shape, sterically obstructing their binding. Mutations in Bcr-Abl kinase interfering with imatinib[12] are one example (Figure 1). (ii) Allosteric drugs bind away from the active or functional site.[102–111] Since these sites are not conserved across the family, they are typically more specific thus with lesser side effects. Furthermore, since they bind at a distance, they work by promoting a shift in the conformational ensemble toward a conformation with an altered active site, thus enabling modulation of protein activity.[112–115] They operate by impeding or fine-tuning high affinity ligand or cofactor binding. They do, however, require sufficiently large, or deep, pockets in the protein surface with chemically favorable residues lining it, with the pockets commonly a priori unknown.[116–118] At the same time, discovering appropriate surface pockets can be challenging, as the case of KRas4B has demonstrated.[1,119–122] An alternative approach involves discovering rescue mutations and mimicking them.[108,123] The allosteric mutations in the myristate-binding pocket of Bcr-Abl that were able to promote an inactive state that could bind the inhibitor can provide an example (Figure 1). They overcame the T315I gatekeeper drug resistance mutation to competitive drugs such as nilotinib that prevented it and were subsequently mimicked by allosteric inhibitor GNF-5.[12] Recently, (iii) combinations of orthosteric plus allosteric drugs have been shown to be successful in countering drug resistance that emerged to the orthosteric drug, and blocked its active site binding.[9,124] The modulation of the active site structure prompted by the allosteric drug restored effective binding to a competitive inhibitor.[12] Protease-activated receptor-2 (PAR2) provides another potential example[125] as does B-Raf.[126] (iv) The drug can bind non-covalently, which is the case most of the time, or especially in the absence of sufficiently deep pockets, it can be covalent.[121,127–137] Examples that target the KRas4B^{G12C} mutant include AMG510 (Sotorasib, the first-ever KRas drug to be approved by FDA),[138,139] MRTX849 (Phase I/II),[140–142] JNJ-74699157 (formerly ARS-3248; Phase I, earlier ARS-1620),[143] and LY3499446 (Phase I/II). MRTX849 is a promising clinical candidate[134,135] as are AMG and



FIGURE 1 Bcr-Abl kinase domain structure. Bcr-Abl can be drugged with a combination of orthosteric and allosteric inhibitors to hinder the development of drug resistance. Crystal structure of Bcr-Abl kinase domain (PDB: 3K5V) with the orthosteric inhibitor imatinib (green) and the allosteric inhibitor GNF-2 (pink). Highlights of the ATP binding pocket with imatinib (upper right panel) and the myristate binding pocket with GNF-2 (lower right panel) [Color figure can be viewed at wileyonlinelibrary.com]

MRTX. Covalent attachment requires a cysteine and a sufficiently specific surrounding molecular surface, which allows a less active drug warhead. Since there are numerous cysteines in cavities in the proteome, this is likely to reduce toxicity. Covalent drugs have achieved remarkable successes in drugging the "undruggable" KRas4B. Recently, tyrosine has also been shown to anchor covalent drugs. A covalent inhibitor that forms a bond with a tyrosine was recently successfully placed on Ral which is almost identical to Ras GTPases.[144] Since covalent drugs are long-lived, protein degradation through covalently attached proteolysis targeting chimeras (PROTACs) are being pursued.[145–150]

4 | PROTEIN ENSEMBLES, DRIVER MUTATIONS, AND DRUGS

Biological functions are regulated by conformational states. Since proteins are highly dynamic molecules, evaluation of the protein structural ensembles is superior to that of a single state. Even if seemingly minor, a residue substitution would affect the conformational ensemble, and depending on the extent and type of the change, function.[151–153] Understanding the effects of single and double mutations on the conformational ensembles is crucial.[153–155] Intuitively, when a strong driver occurs on a protein, 90% of the conformations in the ensemble can be in an active state, and about 50%–75% of the conformations can be in an active state for a driver mutation. Weak drivers and strong latent drivers also can activate around 50% and 25% of the ensemble, respectively. A strong driver may be able to switch almost the entire set of the populations to a fully active state; but to facilitate such a fully activated state, other mutations need to cooperate. Ideally, personalized medicine would explore comprehensively such driver cooperation mechanisms across tissues.[156]

As we discuss below, recently, multiple driver mutations have been discovered in the same protein. They have shown larger sensitivity to orthosteric drugs.[4,5,9] No allosteric drug was tested since to date none exists for PI3K, the lipid kinase which was analyzed. It is however expected that the details and extents of the conformational changes that the mutations promote will differ, which may open new vistas for more specific drug discovery.[7]

5 | MOLECULAR ACTIVATION MECHANISM MATTERS IN DRUG DISCOVERY

Proteins act through structural changes and drugs aim to block their action. A competitive drug binding mechanism is powerful since it directly blocks ligand docking.[125,157–166] A noncompetitive drug binding can be powerful by altering the active site shape, leading to the same outcome.[167–177] These drug actions typically target the *active* conformation. Most drugs in the market work in this way. However, counter to intuition, drugs can also work by binding to the *inactive* state. These drugs can work by capturing the *inactive* or *nonfunctional* conformation and tampering with its mechanism of activation. The mechanism of activation can guide the decision on which type of drug to select, should it be one that targets the *active* or the *inactive* state.

A biological macromolecule exists not only in the shape captured in the crystal structure, but in a large ensemble of shapes.[178–184] Their distributions reflect their relative stabilities.[104,113,185–210] In the resting protein state, which is the state where most proteins (except for repressors) spend most of their lifetime, the protein is *inactive*. This is the more stable state under these conditions. Upon stimulation through some incoming cue, for example, a phosphorylated receptor motif as in the case of receptor tyrosine kinase (RTK), or a phosphorylated calmodulin,[211,212] or binding to another signal-activated molecule, as in the case of Raf binding to active Ras, or phosphorylation events as in the cases of AKT (a.k.a. protein kinase B) protein kinase,[213–216] mitogen-activated protein kinase kinase (MEK), and extracellular signal regulated kinase (ERK),[217,218] the relative stabilities of the *active* versus the *inactive* states change. This happens since binding events, noncovalent or covalent, and other changes in the macromolecular environment involve the formation and breaking of

interactions.[103,105,194,197,203,207,219–233] The alterations stabilize the *active* state (and/or destabilize the *inactive* state), leading to a shift in the ensemble from the *inactive* to the *active* state.[7,15,155,234] Driver mutations mimic the activation mechanism of the wild type. Like the native regulated scenarios, they also act by forming and/or breaking interactions incurred by the different chemical and geometrical properties of the substituted residue. The structural perturbations that they promote propagate in the structure just like the native scenarios do.[235,236] They hijack the same activation, and like them, can act to relieve the autoinhibition, expose surfaces to the membrane, and rearrange protein organization. However, the different mutations populate distinct conformations, thus preferred partners and signaling pathways as recently shown by the elegant work of Westover and his colleague[237] for $KRas^{Q61H}$ versus $KRas^{G12D}$ or $KRas^{G13D}$. That observation extends the group's earlier work[238] on $KRas^{Q61H}$ low GTPase activity, as well as higher affinity to Raf vs PI3Kα and the consequent enhanced mitogen-activated protein kinase (MAPK) signaling as compared to PI3Kα/AKT/mechanistic target of rapamycin (mTOR) signaling.

As an example, protein kinase activation involves switching the αC-helix-out to αC-helix-in (Figure 2A). This involves rotation and shift, with a salt bridge between the β3-Lys and the αC-Glu, and R-spine assembly.[104] The hydrophobic R-spine, with two aromatic residues in the C-lobe and two aliphatic residues in the N-lobe, is assembled in the active state, parallel to the C-spine, and disassembled in the inactive state (Figure 2B). Stabilized R-spine promotes activation. Driver mutations can stabilize the αC-helix-in and/or break interactions that stabilize the αC-helix-out. The L858R driver in epidermal growth factor receptor (EGFR) within a hydrophobic region is such a case. Replacing a hydrophobic by a positively charged residue breaks the hydrophobic interactions destabilizing the inactive αC-helix-out conformation and stabilizes the active αC-helix-in organization through heterodimerization. The T790M mutation in EGFR, T315I in Bcr-Abl, T334I in Abl1 (c-Abl), T338(341)I in Src, T670I in c-Kit, and T674I in platelet-derived growth factor receptor α (PDGFRα), all introduce a hydrophobic residue that stabilizes the hydrophobic R-spine, similarly shifting the ensemble toward the active conformation.[232,239] In PI3Kα lipid kinase, activation involves the binding of the nSH2 domain in the p85α subunit to RTK's phosphorylated tyrosine motif pYXXM in the C-terminal, leading to exposure of the active site in the kinase domain in the p110α subunit at the membrane. With charge reversal,[240] major driver mutations E542K and E545K in the helical domain relieve the nSH2 autoinhibition,[86] and through a series of conformational changes, lead to the same outcome.[7] Oncogenic replacements of Glu81, Gly106, Arg108, Lys111, and Gly118 in the adapter binding domain (ABD) also promote exposure.[14] These mutations act by lowering the transition state barrier (*ka*). The H1047R hotspot acts by increasing the population time (*km*) of the PIP_2 in the active site.

Thus, activation of kinases involves a shift in the ensemble from the *inactive* to the *active* state. Can drugs work by reversing this shift? Designing allosteric drugs that would shift the ensemble back to the *inactive* state is challenging. Allosteric drugs for kinases commonly aim at altering the shape of the active site to enable occluded orthosteric drugs to dock.[12] That is, kinase inhibitors work by *blocking the mechanism of activation*—not by targeting the active or inactive states. Nonetheless, there are exceptions that are based on the location to which the drug binds. Raf is one example[126,241,242] where a drug can bind to the inactive monomer at the dimeric interface to block activation by interfering with dimerization.

6 | INHIBITION OF AN ACTIVATION MECHANISM INVOLVING AN INACTIVE STATE

Kinases provide an example of inhibition of the *active* state. This however is not the case for the superfamily of Ras GTPases where a pioneering strategy has recently shown that inhibitors targeting the *inactive*, *nonfunctional* state can work and to date successfully advance through clinical trials. This disparity between kinases and small GTPases reflects the distinction of the activation scenarios between the two classes of proteins.[3]

Different from kinases, Ras activation cannot be described by the free energy as a shift of the ensemble from the *inactive* to the *active* state and neither can its activation by driver mutations. Instead, Ras is activated by



FIGURE 2 Structural insights into the driver mutations in kinases. (A) The L858R driver mutation in EGFR destabilizes the inactive structure (PDB: 1XKK) and stabilizes the active conformation (PDB: 6JX4). (B) The "gatekeeper" mutations in EGFR (PDB: 6JX4), Bcr-Abl (PDB: 2GQG), Src (PDB: 1YI6), c-Kit (PDB: 1PKG), and PDFGRα (PDB: 6JOI) stabilize the R-spine for the active conformation. The mutated residues were modeled based on the crystal structures [Color figure can be viewed at wileyonlinelibrary.com]

exchange of GDP by GTP through the Son of Sevenless (SOS), a Ras-specific guanine nucleotide exchange factor (GEF), which is recruited by Grb2 adapter protein[243–247] and is deactivated by hydrolysis of GTP to GDP by GTPase-activating proteins (GAPs).[246] Ras drivers work by interfering with the deactivating mechanisms. Stronger drivers block hydrolysis. Weaker, or tissue-specific drivers work by meddling with the nucleotide exchange. The strong drivers involve substitution of Gly12 and Gly13 by residues with long side chains which prevent GAP from inserting its arginine finger. The "finger" mediates proton transfer from an attacking water molecule to another, and

a subsequent different proton from that water molecule to GTP.[239,248,249] Gln61, also a strong driver, stabilizes the transient OH^- and $H3O^+$ ions to reduce the transition state barrier.[250] Weaker driver mutations, for example, $KRas4B^{A146T}$, aid nucleotide exchange back to GTP. Multiple approaches have been attempted for inhibition of Ras *active* states which to date have proven challenging. Apart from the GTP binding site, Ras lacks a deep pocket. However, the high millimolar range concentration of GTP in the cell and its picomolar affinity, results in approximately 75% of $KRas^{G12C}$ molecules interacting with it, making it formidable to compete even though hydrolysis is the highest for the $KRas4B^{G12C}$ mutant.[238] Approaches that target the active state include blocking cysteine farnesylation at the C-terminal, translocation from the endoplasmic reticulum and thus Ras anchoring to the membrane,[65–68] Ras–GEF interaction, dimerization,[69,70] Ras–Raf interaction,[71,72] synthetic single domain monobodies,[46,73] and more.[44,221,251–257] These were all extensively reviewed.[3] Several possible factors may have contributed to failures, including membrane liquidity, toxicity (e.g., FTase farnesylates additional proteins), lack of specificity and/or replacement by another prenyl moiety (e.g., geranylgeranylation), as in the case of blocking farnesyl transferase.

In an innovative strategy, Shokat and his colleagues covalently linked an inhibitor to the cysteine in *inactive* $KRas^{G12C}$ tampering with nucleotide exchange.[1] Their millimolar affinity inhibitor prompted subsequent higher-affinity drug development,[59] including AMG510 (Sotorasib, the first-ever KRas drug to be approved by FDA),[138,139] MRTX849 (Phase I/II),[140–142] JNJ-74699157 (formerly ARS-3248; Phase I, earlier ARS-1620),[143] and LY3499446 (Phase I/II) (reviewed in Nussinov et al.[3]). Responses of patients harboring the mutation that were given MRTX849 have been promising[134,135] as were those of Phase 1 AMG510 with advanced colorectal cancer and several other tumors.[139] To make the inhibited $KRas^{G12C}$ degradable, a C12 covalently linked PROTACs molecule (a proteolysis targeting chimera consisting of two linked molecules where one end binds ubiquitin ligase, and the other binds Ras) with a potent MRTX849 warhead (LC-2) was developed. LC-2 is an E3 ligase VHL-mediated degrading agent.[145] Exploiting cysteine disulfide tethering,[1] Shokat and his colleagues synthesized drugs binding to a pocket in the Switch II region near the nucleotide-binding pocket. This SII-P pocket is present only in the GDP-bound KRas4B, but not in the active, GTP-bound state. Binding to the inactive KRas4B promoted conformational changes in the Switch I and II regions which disfavored binding of Ras regulators and effectors, indicating that inhibitor binding to the *inactive* conformation is a feasible pharmacological route.[46] ARS-1620[143] has shown a more potent drug action in quenching Raf activation thus MAPK signaling.

A druggable pocket between Switch I and II[69,72,258,259] that exists in both active and inactive conformations of KRas4B proteins have also been targeted.[119] This SI/II-pocket is shallow and polar thus previously considered "undruggable." Initiating from weak binding candidates and structure-based drug design Kessler and his colleagues discovered BI-2852 (compound 1), a nanomolar inhibitor that curtails MAPK and PI3K/AKT signaling decreasing cellular proliferation. Inspection of the neighboring unit cell in the crystal structure of KRas4B–BI-2852 complex suggested that the inhibitor promotes KRas4B dimerization with two inhibitors with rotational symmetry.[260] Further structural scrutiny[3,119] pointed to formation of a nonfunctional KRas4B dimer, stabilized by two molecules of the BI-2852 inhibitor. Subsequent dimeric Switch I/II compound 2 pocket binders stabilized the active $KRas4B^{G12D}$ dimers with a K_D of 3.8 μM.[120] Soaking the crystal with compound 2 yielded a 1.9 Å resolution structure.[261] Co-crystallization obtained 1.57 Å resolution dimer, with an interface resembling that observed with BI-2852 and earlier proposed by modeling and MD simulations of active KRas4B molecules.[262]

Mutant Ral GTPases were also targeted by drugs binding to their GDP-bound state exploiting a new pocket[263] which displays a $KRas^{G12C}$-like mutation. A subsequent covalent Ral inhibitor with a novel tyrosine linkage was developed.[144] Ral proteins belong to the Ras superfamily and are almost identical to Ras. Blocking Rheb GTPase has also been explored albeit not targeting its inactive state.[264]

Thus, kinases and GTPases have distinct mechanisms of activation of their wild-type species. Their driver mutations mimic their respective mechanisms, and their drugs target their mechanisms of activation—rather than their active or inactive states.

7 | HOW TO IDENTIFY CANDIDATES FOR ACTIVE (OR INACTIVE) STATE PHARMACOLOGY?

As an example, we consider the PI3Kα lipid kinase. PI3Kα is activated at the membrane by activated RTKs and Ras proteins.[14,211,265–267] It's catalytic p110α subunit contains the kinase domain. The nSH2α and cSH2α domains in the p85α regulatory subunit have high affinity to the phosphorylated tyrosine motif (pYXXM) in the C-terminal of RTKs.[268,269] nSH2 autoinhibits the catalytic p110α by precluding its contact with the membrane where the PIP_2 signaling lipid substrate resides. The RTK–nSH2 interaction outcompetes that between the p85α and the p110α subunits, initiating a series of conformational changes that culminate in PI3Kα activation.[270] Hydrogen/deuterium exchange mass spectrometry (HDX-MS) data point to four prerequisites in activation: releasing the interaction of nSH2 with the helical domain of the p110α, breaking the interaction of the iSH2α domain in the p85α with the p110α C2 domain, movement of the ABD p110α domain which exposes the catalytic kinase domain surface to the membrane, and finally, lipid interaction.[17] nSH2 release also promotes structural rearrangement in the C-lobe of the kinase domain, resulting in a reduced ATP-substrate distance that permits phosphoryl transfer from ATP to the PIP_2 to generate phosphatidylinositol-3,4,5-bisphosphate (PIP_3). Notably, the regions where these actions take place do not interact directly with the catalytic sites. Whereas the crystal structures provide the key data and HDX-MS capture key activation events, modeling and molecular dynamics simulations can outline exactly how these events which are far away from the catalytic site regulate activation, and how the decisive conformational changes switch the inactive to the active state at the membrane. It can also elucidate how mutations promote activation and offer an allosteric inhibitor strategy.[7,9,10,15,15,240,271–275] This also holds for Ras and its other effectors (e.g., Refs.[236,276–278]).

Lipid kinase domains in PI3Ks coincide with the kinase domains in protein kinases. In protein kinases, the signature features of the DFG motif, αC-helix, and the activation loop (a-loop) specify the activity status of the enzyme.[85,279] In PI3K lipid kinases, signature features include the activation loop and the kinase domain helix 11 (kα11). In the inactive state the activation loop is collapsed and the kinase domain helix 11 is in the IN state. In the active state, the loop is extended and kα11 is in the OUT state. nSH2 regulates activation, catalysis, and autoinhibition through the a-loop. In the wild type, the inactive state is more stable. The altered interactions in the mutants render the active state of higher stability, driving the conformational change and activation. That however is not the case for Ras proteins whose activation status involves binding to GTP and retaining it.[3]

8 | DRUGS CAN ACT ON INACTIVE KINASES AND ON ACTIVE GTPASES

There are exceptions. Drugs can act on inactive kinases and on active GTPases. As an example, B-Raf mutations have been grouped into three classes[241] (Figure 3). B-Raf^{V600E} mutations belong to Class I. Mutations falling into Class I activate Raf by mimicking activation loop phosphorylation, causing B-Raf to adopt an active configuration.[280–282] Class II includes constitutive dimers. The activating mutations increase the dimer binding affinity, thus also relinquishing Ras help. A combination of strong latent drivers[154,155] at or close to the dimer interface can lead to this outcome. Class III features mutations that enhance dimerization, but still need active Ras. A drug that binds the *inactive* monomer at the dimer interface and maims dimerization is a successful inhibitor.[126,242] In another remarkable kinase example, allosteric compounds that bind to the myristate-binding pocket of Bcr-Abl can promote an inactive state (Figure 1), overcoming drug resistance mutations in the ATP-binding pocket as well as the T315I gatekeeper mutation (Figure 2B) restoring the inhibitory activity of ATP-competitive drugs in cellular and murine models of chronic myelogenous leukemia (CML).[12] At the same time, an inhibitor binding at the effector binding site of *active* Ras can still cripple Raf binding and MAPK signaling.



FIGURE 3 B-Raf mutations and inhibitors. B-Raf kinase domain structure with highlighted ^{594}DFG^{596} motif (left panel). Examples of B-Raf inhibitors (right panels). Inhibitors can bind to active or inactive B-Raf. GDC-0879 is a Type 1 inhibitor that binds to the active form of B-Raf with αC-helix-in and DFG-in. Vemurafenib is a Type 1½ inhibitor that binds to an inactive form of B-Raf with αC-helix-out and DFG-in. Sorafenib is a Type 2 inhibitor that binds to an inactive form of B-Raf with αC-helix-in and DFG-out. The αC-helix and the side chains of DFG motif are colored blue and black, respectively. In the cartoons, the crystal structures (PDB: 4MNE, 4MNF) were used to model the protein structures. The mechanism of activation for B-Raf mutation classes (bottom panels). B-Raf mutations are grouped into three classes based on activation mechanisms. B-Raf kinase domain with Class I (pink), Class II (green), and Class III (gray) mutation sites highlighted. Class I mutations are Ras and dimer independent. Class II mutations are Ras independent but require homodimerization. Class III mutations require activation via mutated Ras and dimerization with wild-type C-Raf [Color figure can be viewed at wileyonlinelibrary.com]

There can also be the same allele (*in cis*) double (multiple) mutations. Double driver mutations have been discovered in *PIK3CA* in human breast cancers.[4] They hyperactivated PI3K signaling and enhanced tumor growth which was more responsive to PI3K inhibitors as compared with single mutation tumors. A pan-cancer analysis of 60,954 samples identified 14 pan-cancer and six cancer-type-specific oncogenes where multiple *in cis* mutations occur more frequently than expected.[5] In PI3Kα, combinations included E453K/Q, E726K, and M1043V/I with E542K, E545K, and H1047R.[4] The first are weaker while the second stronger. As examples of the mechanisms, E453K/Q is in the C2 domain; E726K in the N-lobe of the kinase domain, and M1043V/I in the C-lobe (Figure 4). Like H1047R, with a positive charge E726K assists in membrane interaction. H1047 and M1043 are at the regulatory arch of kinase domain C-lobe. M1043 is buried, strengthening the hydrophobic core. E542K and E545K are in the helical domain, replacing RTK binding to the p85α to relieve the autoinhibition.[7] Altogether, they promote oncogenic cell growth and proliferation by contributing additively.[4,6] Since they mimic the activation mechanism,



FIGURE 4 PI3Kα structure and mutations. A modeled PI3Kα structure (left panel) based on the crystal structure (PDB: 4OVV). PI3Kα is an obligate heterodimer composed of the p110α catalytic and p85α regulatory subunits. Mutations in the p110α subunit of PI3Kα (right panel). The p110α subunit in PI3Kα contains the hotspot (E542K, E545K in the helical domain; H1047R in the kinase domain) and weak (R38H/C, R88Q, R93Q, R108H, and G118D in the ABD; N345R/K, C420R/K, and E453K/Q in the C2 domain; and E726K, M1043V/I in the kinase domain) driver mutations [Color figure can be viewed at wileyonlinelibrary.com]

they are unlikely to change pharmacological decisions. However, structural perturbations incurred by two mutations likely differ from those incurred by one, which may affect drug designs.

9 | IN DRUG RESISTANCE, CO-OCCURRING MUTATIONS CAN BE ON THE SAME ALLELE AND PATHWAY, OR ON DIFFERENT PATHWAYS

More challenging scenarios include combinations of mutations harbored in different proteins in the same or distinct signaling pathways. Such combinations are likely to have emerged during cancer progression and metastasis calling for combinatorial drug regimes. No recurring cancer-causing mutations that were specific to metastatic tumors were observed, with most (96%) of the driver mutations being clonal.[283] Large-scale pan-cancer analyses on metastatic cancer tissue identified cancer drivers and mutation hotspots, observing that the mutational landscapes of metastatic genomes do not differ from those of primary tumors.[283,284] This suggested that metastasis-specific mutations are not responsible for the spreading of cancer. Forecasting the emergence of pathways harboring drug resistance mutations may involve detecting regulatory genomic regions with sparser chromatin density[285] and scanning and analyzing pre-existing and emerging mutations.[286]

Large-scale cancer genome sequencing projects including The Cancer Genome Atlas (TCGA)[287] and the International Cancer Genome Consortium (ICGC) obtained genomic profiling of more than 10,000 tumors. The AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE)[288] led to the accumulation of a large volume of mutational profiles in human cancers. Transformation of these high-volume data to clinically interpretable knowledge and optimizing the treatment strategies based on the findings derived from these data are proceeding at a considerable pace. Recent statistical analysis[156] on somatic mutation profiles of approximately 80,000 tumors from pan-cancer data sets of TCGA and GENIE detected significant double mutations occurrences on the same alleles.[288–290] The tumor samples are from 671 cancer subtypes and 34 tissues. 228 significant double mutations

are identified on 35 genes including of 20 tumor suppressor genes (TSG), 12 oncogenes (OG), and the rest labeled as both.

Figure 5A presents tumors in brain, bowel, stomach, bladder, uterus, breast, and lung tissues harboring double mutations on four TSGs (*TSC1*, *APC*, *NF1*, and *PTEN*) and four OGs (*BRAF*, *KRAS*, *PIK3CA*, and *EGFR*). Although double mutations are extremely rare, the accumulation of the same allele double mutations is tissue specific. *PIK3CA* double mutations, for instance, are prevalent in breast, bowel, and uterine tumors; *EGFR* and *KRAS* double mutations accumulate mostly in lung tumors. *APC* double mutations are populated in bowel tissue; *BRAF* and *TSC1* double mutations are prominent in brain tissue.[156] Pan-cancer data revealed that double mutation components on the same protein rarely belong to the same domain. This can be attributed to the fact that oncogenic signaling can be boosted by co-occurring mutations on different domains; but on the same domain, it may not be the optimal way



FIGURE 5 Co-occurrence patterns of mutations on same genes and pathways. (A) Prevalence of the double mutant tumors on four tumor suppressor genes, TSGs (*TSC1*, *APC*, *NF1*, and *PTEN*) and four oncogenes, OGs (*BRAF*, *KRAS*, *PIK3CA*, and *EGFR*) among the tumors in brain, bowel, stomach, bladder, uterus, breast, and lung tissues. Source nodes are genes harboring significant double mutations, and target nodes are the tissues enriched with double mutant tumors. Green source nodes are tumor suppressors, red source nodes are oncogenes. Size of the arc proportional to the number of double mutant tumors, arc color is compatible with the target node color. (B) Heatmap shows fraction of different gene double mutant tumors where constituents of the double mutations belong to the pathways on the *x*-axis and y-axis. Fractions are calculated based on the ratio of the double mutant tumors from pathway 1 and pathway 2 to the number of double mutant tumors where one component from pathway 1 or pathway 2. (C) Fraction of different gene double mutant tumors in breast, brain, bowel, lung, and uterus tissues. More than 25% of double mutant tumors where one component from PI3K and the other from TP53 pathways are accumulated in breast tissue. The fraction of double mutant tumors with components from PI3K and RTK/Ras pathways is ~5% [Color figure can be viewed at wileyonlinelibrary.com]

having another functionally equivalent mutation to provide growth advantage. In terms of precision oncology and drug resistance mechanisms, Nussinov et al.[155,285] proposed that it is vital to understand whether signaling pathways are redundant or parallel. Redundant pathways involve members of the same protein family and perform the same functions; pathways that involve evolutionary-independent proteins, are parallel. This distinction helps clarify the mechanisms of network rewiring and hence drug resistance. Remarkably, examination of the tendency of co-occurring mutations among genes belonging to the 10 canonical signaling pathways[287] and subunits of the cohesin complex (RAD21, STAG2, and SMC3) revealed that although not all genes in the listed pathways are covered by the data, genes belonging to the same pathway rarely harbor co-occurring mutations. Figure 5B indicates that only cohesin complex subunits, Notch and PI3K pathways co-mutate between 10% and 20% with a gene belonging to the same pathway; this fraction is below 10% for the remaining pathways. Single mutations in approximately 47% of the double mutant tumors are in genes in the RTK/Ras and TP53 pathways.

Figure 5C shows that PI3K pathway genes are co-mutated with the TP53 pathway (~25%) in breast tissue, RTK/Ras (~40%), and Notch (~25%) pathways in the bowel, and cell cycle pathway (~40%) in brain tissue tumors. The RTK/Ras and the cell cycle pathways are also co-mutated in the lung (~15%) and Wnt pathway in bowel (~80%) tumors. 50% of the tumors with mutations on genes from Notch and cell cycle pathways belong to brain tissue. Thus, certain pathways are co-mutated depending on the tissue in which the tumor is located; this offers a preliminary evaluation scale worth further investigation.

10 | DOUBLE MUTATIONS ON THE SAME ALLELE CAN RESULT IN DRAMATIC PHENOTYPIC ALTERATIONS

In "oncogenic addiction" the growth of the cancer cell can be targeted through a single oncogene. In certain genes, such as *PIK3CA*, double mutations increase the growth rate of the tumor, which can be dramatically slowed upon treatment with drugs targeting these genes.[4] Availability of the cell line and patient-derived xenograft data sets with treatment response information enables comparison of responses to drug therapy for different mutation status. Xenografts are especially well suited for the observation of wild-type, single and double mutation effects, as xenografts often provide untreated and treated versions with tumor volume information. Drug treatment responses for same-allele double mutations in cell lines and xenografts, which contain a single mutation and a wild type, differ. Figure 6A presents the *PIK3CA* wild-type, single (H1047), and double mutant (H1047/P539) breast cancer gene (BRCA) cell lines obtained from Cell Model Passports[291] and Cancerrxgene[292] databases. In AlloDB, the mutation P539R is cataloged as an allosteric mutation.[293] *PIK3CA* wild-type cell line does not contain same/different allele double mutation, and the single mutant cell line does not have any same allele double mutation. The three cell lines were treated with 39 common drugs targeting the six signaling pathways including the PI3K/mTOR, RTK/Ras, EGFR, Wnt, ERK, and cell cycle pathways. Drug responses of wild-type, single mutant, and double mutant cell lines are significantly different from each other (Mann–Whitney U Test, $p = 0.05$). The analysis included drugs with z-score < −0.5 in the double mutant cell line (BT-20). Moreover, it helps to observe the changes in tumor volumes after individual drug therapies. For double mutations in patient-derived BRCA xenograft models,[294] the volume of the tumor in the untreated double mutant xenograft increases more aggressively compared with the wild-type and single mutant xenografts (Figure 6B). The growth rate of the double mutant xenograft (*PIK3CA*$^{H1047/E726}$) is larger than the wild-type and the single mutant (*PIK3CA*^{H1047}). Also, treatments with drugs such as Paclitaxel (microtubule stabilizer), LEE011 (Ribociclib, CDK inhibitor), Trastuzumab (anti-HER2), BYL719 (Alpelisib, PI3K inhibitor), LJM716 (anti-HER3), and Tamoxifen (antiestrogen) slow down the tumor growth rate of the double mutant xenograft. As the available clinical drug treatment data increase, it might be possible to test the effects of double mutations in tumor suppressors that may cause loss of function on tumor growth and drug response.



FIGURE 6 BRCA cell lines and xenografts drug responses. (A) Violin plot showing drug response distributions of *PIK3CA* wild-type, single (H1047), and double mutant (H1047/P539) cell lines. Drugs with z-score < −0.5 in the double mutant cell line (BT-20) are covered. 18 drugs (out of 39 common drugs) target the PI3K/mTOR signaling pathway. (B) Comparisons of tumor growth rates of wild type, single, and double mutant xenografts before and after treatments with several drugs. Double mutant xenograft shows better treatments with drugs, slowing down tumor growth rate [Color figure can be viewed at wileyonlinelibrary.com]

11 | PRECISION ONCOLOGY DECISIONS: THE CELLULAR NETWORK IS A CHIEF ACTOR IN CANCER

Even though commonly not emphasized, the rewired cell-specific cellular network emerging in drug resistance is a chief player in cancer.[20] Advances in genomics and interactomics are now making it possible to observe how disease mutations perturb protein–protein interaction networks within human cells.[295] The rewiring is driven by the altered cellular environment and the dynamic chromatin density at the regulatory regions of genes encoding proteins in the same or alternative pathways. Regions with lower chromatin density are more likely to be accessible to the transcription machinery[285,296,297] or to undergo some conformational remodeling leading to a similar outcome. Cell transformation involves alterations in genes regulating cell growth, division, and apoptosis and in pathway cross-talks. Cancer typically emerges from genetic changes involving uncontrolled growth and broken antiproliferative cellular responses. Both point to a rewired cellular network. That the network is a chief player can also be seen from genome-wide analysis of oncogene signaling. One example involves melanoma *BRAF* data which indicated that distinct pathways promote distinct melanomas.[298] In another, PI3K (*PIK3CA*), also a highly mutated gene in cancers such as breast, colon and endometrial cancer[299,300] merges incoming growth and survival cues from RTKs and Ras and acts on them by converting signaling lipid PIP_2 to PIP_3, and transmits the signals to the mTOR, MAPK, FOXO1 (forkhead box protein O1), and GSK3β (glycogen synthase kinase 3β) pathways. However, the gene

encoding the p85α subunit of PI3Kα is mutated in only approximately 10% of colorectal cancer patients raising the question whether this points to altered signaling that could be harnessed in drug resistance by the cancer cell.[249]

Networks emerge to coordinate key processes during development, including proliferation, apoptosis, and differentiation. Cancer cells rewire them. Cancer commonly involves co-occurring mutations and deregulation of signaling pathways can take place upstream or downstream.[20] If upstream it can be the outcome of, for example, overexpression of growth factors[301,302] or deregulating mutations in cell surface receptors. If downstream, activation mutations can bypass the requirement of incoming signals, as in the case of activating PI3K mutations that release the autoinhibition or obliviate the need for active, GTP-bound Ras signals. Another example involves PKC (protein kinase C) which can activate the MAPK pathway bypassing Ras activation[303] as can Raf by multiple classes of activating mutations.[304,305] The molecular checkpoint switches are often crippled in cancer, with the cell losing control of regulated progress through the cell cycle phases.[232]

The cell-specific network is a map of protein–protein interactions.[285,306] The proteins are nodes and the network controlled by network motifs and signal integration mechanisms. Cell- and state-specific networks vary, with some signaling pathways becoming more populated whereas others less so. Each node may receive several allostery-promoting signals through, for example, binding proteins or small ligands such as cofactors, and post-translational modifications such as phosphorylation, methylation, and ubiquitylation. The protein (node) integrates the signals and transmits a response.[225] Protein expression is controlled by the accessibility of the corresponding chromatin segments.[285,297] It is organ (tissue) specific and influenced by the cell state which is the outcome of stimuli and development. The accessibility is retained as the cell goes through mitosis,[307] emphasizing the cell-specific profiles of signaling pathways. Chromatin accessibility, thus protein expression, is a key factor determining the populated signaling pathways.

Cancer drivers often display tissue-specific mutational frequencies.[308,309] The distinct distributions of Ras isoforms, KRas, NRas, and HRas, and the statistics of their mutations are one example.[285,309–313] $KRas^{G12D}$ expression and its consequences in colorectal adenocarcinoma (CRC) development as compared with $NRas^{G12D}$ provide a mutant-specific case.[314,315] Distinct occurrences and outcome have also been observed in aggressive myeloproliferative disorder,[316] in intestine carcinoma,[317] and in cancers of the pancreas, colon, and lung as well. However, these may reflect the high signaling levels of MAPK pathway in these cancers. Metastasis-specific mutations were also discovered in *DCC*, *ABCA13*, *TIAM2*, *CREBBP*, *BCL6B*, and *ZNF185* genes, with signaling through distinct pathways during malignant progression.[318] Specific combinations were observed as well in metastatic CRC versus primary cancers.[319]

The cell-specific accessible chromatin regions and the protein–protein interaction networks of a skin cell differ from those of a pancreatic cell. This may explain the distinct functions of specific isoforms among tissues. They are expressed and preferentially interact with proteins which are available in those cells. Mutations emerging in these isoforms are then likely to be preferentially distributed in the specific tissues as well, demonstrating distinct distributions. That is, the mutants of isoforms operate within this landscape clarifying the observed tissue-specific tendencies.[285,308,320,321] Cellular perturbation following inhibition of a mutated target may advance drug resistance. Resistance may give rise to a mutant protein upstream which can bypass the drugged target by recruiting a family member that can substitute for the targeted protein. Higher expression of family proteins may evolve through shifts of the chromatin ensemble which alter genome accessibility. Alternatively, pioneer transcription factors can expose regulatory regions of genes that are tightly packed in the differentiated cell. The expressed proteins can signal through parallel proliferation pathways.[322] These proteins may not be expressed in the tissue-specific differentiated cell states or act in other cell types.[285,308,320,323] BRCA in pancreatic adenocarcinoma can serve as examples. Mutations to BRCA can increase the risk of developing pancreatic cancer and impact treatment decisions.[324]

Cancer cells draw on the chromatin organization to make expression of proteins in alternative signaling pathways possible by modulating their accessibility status.[325,326] They adopt cell lineage principles. Analysis of single-cell chromatin[327] and chromatin dynamics observed stage-specific transcriptional networks,[328] which can be activated in parallel proliferation pathways.[329] Modulation of the chromatin conformational landscape was shown

to relate to developmental and tumor-specific signaling pathways.[330–333] Additional examples emerged from Hi-C experiments[334] and more.[285,335]

Tumors showcase highly heterogeneous populations derived from a common progenitor.[336,337] They challenge pharmaceutical strategies and incite more resistant aggressive cells. Forecasting tumor-specific networks in drug resistance can be powerful in helping physicians select drug combination. A "pathway drug cocktail"[249] can be supported by a redundant pathway resource.[20,323] The National Cancer Institute assembled and made available drug combinations, many of which have been tested.[338] The massive genome sequencing data facilitated oncological drug discovery and a comprehensive database, My Personal Mutanome, was constructed for accelerating the development of precision cancer medicine protocols.[339] A strategy that forecasts the emerging proliferation pathway and the specific proteins based on high-resolution chromatin maps can be immensely useful. New high-resolution electron microscopy techniques which can image promoter regions of oncogenes are making this feasible[323] obtaining more accurate and deliberate targeting of specific cancers at a fraction of the cost.

12 | CONCLUSIONS

Precision medicine is challenging. Efficiency and potency of early decisions are vital for successful late phase clinical trials.[20,323] Recently, inhibition of inactive protein states has shown impressive successes, raising the question which targets can profit and what are the principles and guidelines for pharmacology of the protein inactive state. This has led us to provide a structure-based MOA classification, which updates the traditional phenomenological MOA, including orthosteric and allosteric drugs, and their combination, covalent and noncovalent drugs, and the innovative inactive/active category. *That is - should the active or the inactive state of the protein be targeted*? We suggest that the decision as to which conformation to take up in the design should largely rest on the protein's mechanism of activation. If activation involves switching the conformational ensemble from the inactive to the active state as in kinases, targeting an inactive state conformation has lower chances of success. However, if activation involves another mechanism, e.g. blocking nucleotide hydrolysis or promoting GDP/GTP exchange as in small GTPases, it is more promising. We consider the discovery of double same-allele mutations and their impact on cell proliferation and suggest that like single drivers, *in cis* double drivers also mimic the mechanism of activation although the conformational changes that they promote may differ. Collectively, these emphasize that drug discovery may benefit from deliberating and heeding the natural activation mechanism of the protein designed by nature. Finally, we underscore preeminent role of the cellular network which is deregulated in cancer. Altogether, our classification extends and updates the classical MOA, informs pharmacological decisions, and heralds innovative ingredient consideration offering new concepts in drug design.

ACKNOWLEDGMENTS

The results shown here are in whole or part based upon data generated by TCGA Research Network (https://www.cancer.gov/tcga). The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of the study authors. The cell line data underlying the results presented in the study are available from GDSC (https://www.cancerrxgene.org/downloads), Cell Model Passports (https://cellmodelpassports.sanger.ac.uk/downloads), and The Cancer Dependency Map project (https://depmap.org/portal/download). The PDX data underlying the results presented in the study are available in Gao *et al*. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

This study was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and the Intramural Research Program of the NIH Clinical Center.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

Data are available from the corresponding author upon reasonable request.

ORCID

Ruth Nussinov http://orcid.org/0000-0002-8115-6415
Hyunbum Jang http://orcid.org/0000-0001-9402-4051

REFERENCES

1. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature*. 2013;503(7477):548-551.
2. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the 'undruggable' cancer targets. *Nat Rev Cancer*. 2017;17(8):502-508.
3. Nussinov R, Jang H, Gursoy A, Keskin O, Gaponenko V. Inhibition of nonfunctional Ras. *Cell Chem Biol* 2021;28(2):121-133.
4. Vasan N, Razavi P, Johnson JL, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kalpha inhibitors. *Science*. 2019;366(6466):714-723.
5. Saito Y, Koya J, Araki M, et al. Landscape and function of multiple mutations within individual oncogenes. *Nature*. 2020;582(7810):95-99.
6. Toker A. Double trouble for cancer gene. *Science*. 2019;366(6466):685-686.
7. Zhang M, Jang H, Nussinov R. PI3K driver mutations: a biophysical membrane-centric perspective. *Cancer Res*. 2021;81(2):237-247.
8. Nussinov R, Tsai CJ, Jang H. Why are some driver mutations rare? *Trends Pharmacol Sci*. 2019;40(12):919-929.
9. Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. *Chem Sci*. 2020;11(23):5855-5865.
10. Miller MS, Thompson PE, Gabelli SB. Structural determinants of isoform selectivity in PI3K inhibitors. *Biomolecules*. 2019;9(3).
11. Zhang J, Adrián FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. *Nature*. 2010;463(7280):501-506.
12. Gray NS, Fabbro D. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. *Methods Enzymol*. 2014;548:173-188.
13. Zhang M, Jang H, Nussinov R. The structural basis for Ras activation of PI3Kα lipid kinase. *Phys Chem Chem Phys*. 2019;21(22):12021-12028.
14. Zhang M, Jang H, Nussinov R. The mechanism of PI3Kα activation at the atomic level. *Chem Sci*. 2019;10(12):3671-3680.
15. Nussinov R, Zhang M, Tsai CJ, Jang H. Phosphorylation and driver mutations in PI3Kalpha and PTEN autoinhibition. *Mol Cancer Res*. 2021;19(4):543-548.
16. Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. *Proc Natl Acad Sci U S A*. 2010;107(35):15547-15552.
17. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). *Proc Natl Acad Sci U S A*. 2012;109(38):15259-15264.
18. Nussinov R, Zhang M, Maloney R, Jang H. Drugging multiple same-allele driver mutations in cancer. *Expert Opin Drug Discov*. 2021;16:823-828. https://doi.org/10.1080/17460441.17462021.11905628
19. Peng Y, Alexov E, Basu S. Structural perspective on revealing and altering molecular functions of genetic variants linked with diseases. *Int J Mol Sci*. 2019;20(3):528.
20. Nussinov R, Jang H, Tsai CJ. The structural basis for cancer treatment decisions. *Oncotarget*. 2014;5(17):7285-7302.
21. Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not? *Am Soc Clin Oncol Educ Book*. 2017;37:160-169.

22. Hait WN, Lebowitz PF. Moving upstream in anticancer drug development. *Nat Rev Drug Discov*. 2019;18(3):159-160.
23. Le Magnen C, Shen MM, Abate-Shen C. Lineage plasticity in cancer progression and treatment. *Annu Rev Cancer Biol*. 2018;2:271-289.
24. Bode AM, Dong Z. Recent advances in precision oncology research. *NPJ Precis Oncol*. 2018;2:11.
25. Fountzilas E, Tsimberidou AM. Overview of precision oncology trials: challenges and opportunities. *Expert Rev Clin Pharmacol*. 2018;11(8):797-804.
26. Strovel J, Sittampalam S, Coussens NP, et al. Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies. In: Markossian S, Sittampalam GS, Grossman A, et al, eds. *Assay Guidance Manual*. Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
27. Cheng F, Liang H, Butte AJ, Eng C, Nussinov R. Personal mutanomes meet modern oncology drug discovery and precision health. *Pharmacol Rev*. 2019;71(1):1-19.
28. Csermely P, Korcsmaros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. *Pharmacol Ther*. 2013;138(3):333-408.
29. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol*. 2011;162(6):1239-1249.
30. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. *Future Med Chem*. 2020;12(10):939-947.
31. Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. *Signal Transduct Target Ther*. 2019;4(1):64.
32. Cavasotto CN, Di, Filippo JI. Artificial intelligence in the early stages of drug discovery. *Arch Biochem Biophys*. 2020;698:108730.
33. Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. *Drug Discov Today*. 2021;26(2):511-524.
34. Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. *Expert Opin Drug Discov*. 2020;15(4):397-401.
35. Fang J, Pieper AA, Nussinov R, et al. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. *Med Res Rev*. 2020;40(6):2386-2426.
36. Zeng X, Zhu S, Liu X, Zhou Y, Nussinov R, Cheng F. deepDR: a network-based deep learning approach to in silico drug repositioning. *Bioinformatics*. 2019;35(24):5191-5198.
37. Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. *Signal Transduct Target Ther*. 2020;5(1):113.
38. Zeng X, Zhu S, Hou Y, et al. Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest. *Bioinformatics*. 2020;36(9):2805-2812.
39. FDA. Pharmacologic Class. 2018. Accessed Mar 27, 2018. https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class
40. Chatani PD, Yang JC. Mutated RAS: targeting the "Untargetable" with T Cells. *Clin Cancer Res*. 2020;26(3):537-544.
41. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov*. 2014;13(11):828-851.
42. Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? *Clin Cancer Res*. 2015;21(8):1819-1827.
43. Gentile DR, Rathinaswamy MK, Jenkins ML, et al. Ras binder induces a modified switch-II pocket in GTP and GDP states. *Cell Chemical Biolology*. 2017;24(12):1455-1466.
44. Gorfe AA, Cho KJ. Approaches to inhibiting oncogenic K-Ras. *Small GTPases*. 2021;12(2):96-105.
45. Gupta AK, Wang X, Pagba CV, et al. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. *Chem Biol Drug Des*. 2019;94(2):1441-1456.
46. Khan I, Rhett JM, O'Bryan JP. Therapeutic targeting of RAS: New hope for drugging the "undruggable". *Biochim Biophys Acta, Mol Cell Res*. 2020;1867(2):118570.
47. Liu M, Sjogren AK, Karlsson C, et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. *Proc Natl Acad Sci U S A*. 2010;107(14):6471-6476.
48. Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. *Acta Pharm Sin B*. 2019;9(5):871-879.
49. Lu S, Jang H, Gu S, Zhang J, Nussinov R. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. *Chem Soc Rev*. 2016;45(18):4929-4952.
50. Lu S, Jang H, Zhang J, Nussinov R. Inhibitors of Ras-SOS interactions. *ChemMedChem*. 2016;11(8):814-821.
51. Mattingly RR. Activated Ras as a therapeutic target: constraints on directly targeting Ras isoforms and wild-type versus mutated proteins. *ISRN Oncol*. 2013;2013:536529.
52. McCormick F. Targeting KRAS directly. *Annu Rev Canc Biol*. 2018;2:81-90.
53. Mullard A. Cracking KRAS. *Nat Rev Drug Discov*. 2019;18(12):887-891.

54. O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors. *Pharmacol Res*. 2019;139:503-511.
55. Papke B, Der CJ. Drugging RAS: know the enemy. *Science*. 2017;355(6330):1158-1163.
56. Papke B, Murarka S, Vogel HA, et al. Identification of pyrazolopyridazinones as PDEdelta inhibitors. *Nat Commun*. 2016;7:11360.
57. Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. *Cancer Discov*. 2016;6(3):316-329.
58. Sakamoto K, Kamada Y, Sameshima T, et al. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. *Biochem Biophys Res Commun*. 2017;484(3):605-611.
59. Sheridan C. Grail of RAS cancer drugs within reach. *Nat Biotechnol*. 2020;38(1):6-8.
60. Singh H, Longo DL, Chabner BA. Improving Prospects for Targeting RAS. *J Clin Oncol*. 2015;33(31):3650-3659.
61. Spencer-Smith R, O'Bryan JP. Direct inhibition of RAS: Quest for the Holy Grail? *Semin Cancer Biol*. 2019;54:138-148.
62. Spiegel J, Cromm PM, Zimmermann G, Grossmann TN, Waldmann H. Small-molecule modulation of Ras signaling. *Nat Chem Biol*. 2014;10(8):613-622.
63. Zhang Z, Shokat KM. Bifunctional small-molecule ligands of K-Ras induce its association with immunophilin. *Proteins. Angew Chem Int Ed Engl*. 2019;58(45):16314-16319.
64. Zimmermann G, Papke B, Ismail S, et al. Small-molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. *Nature*. 2013;497(7451):638-642.
65. Baranyi M, Buday L, Hegedus B. K-Ras prenylation as a potential anticancer target. *Cancer Metastasis Rev*. 2020;39:1127-1141.
66. Cheng J, Li Y, Wang X, Dong G, Sheng C. Discovery of novel PDEdelta degraders for the treatment of KRAS mutant colorectal cancer. *J Med Chem*. 2020;63(14):7892-7905.
67. Martín-Gago P, Fansa EK, Klein CH, et al. A PDE6delta-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. *Angew Chem Int Ed Engl*. 2017;56(9):2423-2428.
68. Reid TS, Beese LS. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. *Biochemistry*. 2004;43(22):6877-6884.
69. Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. *Proc Natl Acad Sci USA*. 2012;109(14):5299-5304.
70. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. *Nat Chem Biol*. 2011;7(9):585-587.
71. Bery N, Cruz-Migoni A, Bataille CJ, et al. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. *eLife*. 2018;7.
72. Quevedo CE, Cruz-Migoni A, Bery N, et al. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. *Nat Commun*. 2018;9(1):3169.
73. Spencer-Smith R, Koide A, Zhou Y, et al. Inhibition of RAS function through targeting an allosteric regulatory site. *Nat Chem Biol*. 2017;13(1):62-68.
74. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science*. 2004;304(5670):554.
75. Arafeh R, Samuels Y. PIK3CA in cancer: the past 30 years. *Semin Cancer Biol*. 2019;59:36-49.
76. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. *Curr Top Microbiol Immunol*. 2010;347:21-41.
77. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proc Natl Acad Sci U S A*. 2008;105(7):2652-2657.
78. Pang H, Flinn R, Patsialou A, et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. *Cancer Res*. 2009;69(23):8868-8876.
79. Vatte C, Al Amri AM, Cyrus C, et al. Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer. *Oncol Lett*. 2019;18(3):2427-2433.
80. Masson GR, Williams RL. Structural mechanisms of PTEN regulation. *Csh Perspect Med*. 2020;10(3):a036152.
81. Nguyen HN, Yang JM Jr., Rahdar M, et al. A new class of cancer-associated PTEN mutations defined by membrane translocation defects. *Oncogene*. 2015;34(28):3737-3743.
82. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. *Proc Natl Acad Sci USA*. 1999;96(18):10182-10187.
83. Sun Z, Huang C, He J, et al. PTEN C-terminal deletion causes genomic instability and tumor development. *Cell Rep*. 2014;6(5):844-854.

84. Wang X, Cao X, Sun R, et al. Clinical significance of PTEN deletion, mutation, and loss of PTEN expression in de novo diffuse large B-cell lymphoma. *Neoplasia*. 2018;20(6):574-593.
85. Zhang M, Jang H, Nussinov R. Structural features that distinguish inactive and active PI3K lipid kinases. *J Mol Biol*. 2020;432(22):5849-5859.
86. Nussinov R, Tsai CJ, Jang H. Autoinhibition can identify rare driver mutations and advise pharmacology. *FASEB J*. 2020;34(1):16-29.
87. Liu M, Zhou K, Xu Z, et al. Crystal structure of caspase-11 CARD provides insights into caspase-11 activation. *Cell Discov*. 2020;6:70.
88. Carabias A, Gómez-Hernández M, de Cima S, et al. Mechanisms of autoregulation of C3G, activator of the GTPase Rap1, and its catalytic deregulation in lymphomas. *Sci Signal*. 2020;13(647).
89. Cai R, Liu X, Zhang R, et al. Autoinhibition of TRPV6 channel and regulation by PIP2. *iScience*. 2020;23(9):101444.
90. Bandekar SJ, Arang N, Tully ES, et al. Structure of the C-terminal guanine nucleotide exchange factor module of Trio in an autoinhibited conformation reveals its oncogenic potential. *Sci Signal*. 2019;12(569).
91. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, Verkhivker GM. Sequence and structure signatures of cancer mutation hotspots in protein kinases. *PLoS One*. 2009;4(10):e7485.
92. Tsai CJ, Nussinov R. Emerging allosteric mechanism of EGFR activation in physiological and pathological contexts. *Biophys J*. 2019;117(1):5-13.
93. Gómez-Cavazos JS, Lee KY, Lara-González P, et al. A non-canonical BRCT-phosphopeptide recognition mechanism underlies RhoA activation in cytokinesis. *Curr Biol*. 2020;30(16):3101-3115.
94. Tannous EA, Yates LA, Zhang X, Burgers PM. Mechanism of auto-inhibition and activation of Mec1(ATR) checkpoint kinase. *Nat Struct Mol Biol*. 2021;28(1):50-61.
95. Nussinov R, Zhang M, Tsai CJ, Liao TJ, Fushman D, Jang H. Autoinhibition in Ras effectors Raf, PI3Kalpha, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention. *Biophys Rev*. 2018;10(5):1263-1282.
96. Shevchenko E, Poso A, Pantsar T. The autoinhibited state of MKK4: Phosphorylation, putative dimerization and R134W mutant studied by molecular dynamics simulations. *Comput Struct Biotechnol J*. 2020;18:2687-2698.
97. Liu Y, Bunney TD, Khosa S, et al. Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes. *EBioMedicine*. 2020;51:102607.
98. Hajicek N, Keith NC, Siraliev-Perez E, et al. Structural basis for the activation of PLC-gamma isozymes by phosphorylation and cancer-associated mutations. *eLife*. 2019;8.
99. Chen M, Pan H, Sun L, et al. Structure and regulation of human epithelial cell transforming 2 protein. *Proc Natl Acad Sci USA*. 2020;117(2):1027-1035.
100. Jansma M, Linke-Winnebeck C, Eustermann S, et al. Near-complete structure and model of Tel1ATM from *Chaetomium thermophilum* reveals a robust autoinhibited ATP state. *Structure*. 2020;28(1):83-95.
101. Nussinov R, Tsai CJ. The different ways through which specificity works in orthosteric and allosteric drugs. *Curr Pharm Des*. 2012;18(9):1311-1316.
102. Tsai CJ, Nussinov R. A unified view of "how allostery works". *PLoS Comput Biol*. 2014;10(2):e1003394.
103. Nussinov R, Tsai CJ. Unraveling structural mechanisms of allosteric drug action. *Trends Pharmacol Sci*. 2014;35(5):256-264.
104. Nussinov R, Tsai CJ. Allostery in disease and in drug discovery. *Cell*. 2013;153(2):293-305.
105. Nussinov R, Tsai CJ, Csermely P. Allo-network drugs: harnessing allostery in cellular networks. *Trends Pharmacol Sci*. 2011;32(12):686-693.
106. Huang W, Nussinov R, Zhang J. Computational tools for allosteric drug discovery: site identification and focus library design. *Methods Mol Biol*. 2017;1529:439-446.
107. Liu J, Nussinov R. The role of allostery in the ubiquitin-proteasome system. *Crit Rev Biochem Mol Biol*. 2013;48(2):89-97.
108. Liu J, Nussinov R. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. *Proc Natl Acad Sci USA*. 2008;105(3):901-906.
109. Lu S, Qiu Y, Ni D, He X, Pu J, Zhang J. Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery. *Drug Discov Today*. 2020;25(1):177-184.
110. Song K, Li Q, Gao W, et al. AlloDriver: a method for the identification and analysis of cancer driver targets. *Nucleic Acids Res*. 2019;47(W1):W315-W321.
111. Guarnera E, Berezovsky IN. Allosteric drugs and mutations: chances, challenges, and necessity. *Curr Opin Struct Biol*. 2020;62:149-157.
112. Guarnera E, Berezovsky IN. Toward comprehensive allosteric control over protein activity. *Structure*. 2019;27(5):866-878.
113. Nussinov R, Tsai CJ, Jang H. Dynamic protein allosteric regulation and disease. *Adv Exp Med Biol*. 2019;1163:25-43.

114. Nussinov R, Tsai CJ, Jang H. Does Ras activate Raf and PI3K allosterically? *Front Oncol*. 2019;9:1231.
115. van Veldhoven JPD, Campostrini G, van Gessel CJE, et al. Targeting the Kv11.1 (hERG) channel with allosteric modulators. Synthesis and biological evaluation of three novel series of LUF7346 derivatives. *Eur J Med Chem*. 2020; 212:113033.
116. Lu S, Ji M, Ni D, Zhang J. Discovery of hidden allosteric sites as novel targets for allosteric drug design. *Drug Discov Today*. 2018;23(2):359-365.
117. Song K, Liu X, Huang W, et al. Improved method for the identification and validation of allosteric sites. *J Chem Inf Model*. 2017;57(9):2358-2363.
118. Chen H, Smaill JB, Liu T, Ding K, Lu X. Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics. *J Med Chem*. 2020;63(23):14404-14424.
119. Kessler D, Gmachl M, Mantoulidis A, et al. Drugging an undruggable pocket on KRAS. *Proc Natl Acad Sci U S A*. 2019; 116(32):15823-15829.
120. Kessler D, Gollner A, Gmachl M, et al. Reply to Tran et al.: dimeric KRAS protein-protein interaction stabilizers. *Proc Natl Acad Sci USA*. 2020;117(7):3365-3367.
121. Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? *Cancer Treat Rev*. 2020;84:101974.
122. Zuberi M, Khan I, O'Bryan JP. Inhibition of RAS: proven and potential vulnerabilities. *Biochem Soc Trans*. 2020;48(5): 1831-1841.
123. Tan ZW, Guarnera E, Tee WV, Berezovsky IN. AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations. *Nucleic Acids Res*. 2020;48(W1):W116-W124.
124. Ni D, Li Y, Qiu Y, Pu J, Lu S, Zhang J. Combining allosteric and orthosteric drugs to overcome drug resistance. *Trends Pharmacol Sci*. 2020;41(5):336-348.
125. Kennedy AJ, Sundström L, Geschwindner S, et al. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. *Commun Biol*. 2020;3(1):782.
126. Gunderwala AY, Nimbvikar AA, Cope NJ, Li Z, Wang Z. Development of allosteric BRAF peptide inhibitors targeting the dimer interface of BRAF. *ACS Chem Biol*. 2019;14(7):1471-1480.
127. Nussinov R, Tsai CJ. The design of covalent allosteric drugs. *Annu Rev Pharmacol Toxicol*. 2015;55:249-267.
128. Vita E. 10 years into the resurgence of covalent drugs. *Future Med Chem*. 2021;13(2):193-210.
129. Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT. Advances in covalent kinase inhibitors. *Chem Soc Rev*. 2020;49(9):2617-2687.
130. Lonsdale R, Ward RA. Structure-based design of targeted covalent inhibitors. *Chem Soc Rev*. 2018;47(11): 3816-3830.
131. Mah R, Thomas JR, Shafer CM. Drug discovery considerations in the development of covalent inhibitors. *Bioorg Med Chem Lett*. 2014;24(1):33-39.
132. Du H, Gao J, Weng G, et al. CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors. *Nucleic Acids Res*. 2021;49(D1):D1122-D1129.
133. De Cesco S, Kurian J, Dufresne C, Mittermaier AK, Moitessier N. Covalent inhibitors design and discovery. *Eur J Med Chem*. 2017;138:96-114.
134. Gabizon R, London N. Hitting KRAS When It's Down. *J Med Chem*. 2020;63(13):6677-6678.
135. Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRAS (G12C) inhibitor for the treatment of cancer. *J Med Chem*. 2020;63(13):6679-6693.
136. Uprety D, Adjei AA. KRAS: From undruggable to a druggable cancer target. *Cancer Treat Rev*. 2020;89:102070.
137. Xiao X, Lai M, Song Z, et al. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS(G12C) inhibitors. *Eur J Med Chem*. 2021;213:113082.
138. FDA. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. 2021. Accessed May 28, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc
139. Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. *N Engl J Med*. 2020;383(13):1207-1217.
140. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*. 2019;575(7781):217-223.
141. Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. *Cancer Discov*. 2020;10(1):54-71.
142. Mirati Therapeutics. KRAS G12C Inhibitor. 2020; https://www.mirati.com/pipeline/kras-g12c/
143. Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. *Cell*. 2018; 172(3):578-589.

144. Bum-Erdene K, Liu D, Gonzalez-Gutierrez G, Ghozayel MK, Xu D, Meroueh SO. Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases. *Proc Natl Acad Sci USA*. 2020; 117(13):7131-7139.
145. Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. *ACS Cent Sci*. 2020;6(8):1367-1375.
146. Martin-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. *Eur J Med Chem*. 2021; 210:112993.
147. Wan Y, Yan C, Gao H, Liu T. Small-molecule PROTACs: novel agents for cancer therapy. *Future Med Chem*. 2020; 12(10):915-938.
148. Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: an emerging targeting technique for protein degradation in drug discovery. *BioEssays*. 2018;40(4):e1700247.
149. Li W, Elhassan RM, Hou X, Fang H. Recent advances in small molecule PROTACs for the treatment of cancer. *Curr Med Chem*. 2021;28(24):4893-4909.
150. Khan S, He Y, Zhang X, et al. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. *Oncogene*. 2020;39(26):4909-4924.
151. Bonomi M, Heller GT, Camilloni C, Vendruscolo M. Principles of protein structural ensemble determination. *Curr Opin Struct Biol*. 2017;42:106-116.
152. Nussinov R, Tsai CJ, Jang H. Protein ensembles link genotype to phenotype. *PLoS Comput Biol*. 2019;15(6): e1006648.
153. Zhang N, Chen Y, Lu H, et al. MutaBind2: predicting the impacts of single and multiple mutations on protein-protein interactions. *iScience*. 2020;23(3):100939.
154. Nussinov R, Tsai CJ. 'Latent drivers' expand the cancer mutational landscape. *Curr Opin Struct Biol*. 2015;32:25-32.
155. Nussinov R, Jang H, Tsai CJ, Cheng F. Precision medicine review: rare driver mutations and their biophysical classification. *Biophys Rev*. 2019;11(1):5-19.
156. Yavuz BR, Tsai CJ, Nussinov R, Tuncbag N. Discovery of latent drivers from double mutations in pan-cancer data reveal their clinical impact. *bioRxiv*. 2021. https://doi.org/10.1101/2021.1104.1102.438239
157. Appiah-Kubi P, Olotu FA, Soliman MES. Elucidating the disparate inhibitory mechanisms of novel 1-heteroaryl1,3-propanediamine derivatives and maraviroc towards C-C chemokine receptor 5: insights for structural modifications in HIV-1 drug discovery. *Med Chem*. Published online December 8, 2020.
158. Barkan K, Lagarias P, Stampelou M, et al. Pharmacological characterisation of novel adenosine A3 receptor antagonists. *Sci Rep*. 2020;10(1):20781.
159. Basak S, Kumar A, Ramsey S, et al. High-resolution structures of multiple 5-HT3AR-setron complexes reveal a novel mechanism of competitive inhibition. *eLife*. 2020;9.
160. Kapiainen E, Kihlström MK, Pietilä R, et al. The amino-terminal oligomerization domain of Angiopoietin-2 affects vascular remodeling, mammary gland tumor growth, and lung metastasis in mice. *Cancer Res*. 2021;81(1):129-143.
161. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. *Cancer Res*. 2009;69(15):6232-6240.
162. Chen Y, Zhou X. Research progress of mTOR inhibitors. *Eur J Med Chem*. 2020;208:112820.
163. Jo S, Xu A, Curtis JE, Somani S, MacKerell AD Jr. Computational characterization of antibody-excipient interactions for rational excipient selection using the site identification by ligand competitive saturation-biologics approach. *Mol Pharm*. 2020;17(11):4323-4333.
164. Miles JA, Hobor F, Trinh CH, et al. Selective affimers recognise the BCL-2 family proteins BCL-xL and MCL-1 through noncanonical structural motifs*. *ChemBioChem*. 2021;22(1):232-240.
165. Rubio-Ruiz B, Serran-Aguilera L, Hurtado-Guerrero R, Conejo-Garcia A. Recent advances in the design of choline kinase alpha inhibitors and the molecular basis of their inhibition. *Med Res Rev*. 2021;41(2):902-927.
166. Khan ZM, Real AM, Marsiglia WM, et al. Structural basis for the action of the drug trametinib at KSR-bound MEK. *Nature*. 2020;588(7838):509-514.
167. Balasubramaniam M, Mainali N, Bowroju SK, et al. Structural modeling of GSK3beta implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs. *Sci Rep*. 2020;10(1):18326.
168. Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. *Leuk Res*. 2020;98:106458.
169. Vunnam N, Szymonski S, Hirsova P, Gores GJ, Sachs JN, Hackel BJ. Noncompetitive allosteric antagonism of death receptor 5 by a synthetic affibody ligand. *Biochemistry*. 2020;59(40):3856-3868.
170. Wei S, Zhao T, Wang J, Zhai X. Approach in improving potency and selectivity of kinase inhibitors: Allosteric kinase inhibitors. *Mini Rev Med Chem*. 2021;21(8):991-1003.

171. Niggenaber J, Heyden L, Grabe T, Muller MP, Lategahn J, Rauh D. Complex crystal structures of EGFR with third-generation kinase inhibitors and simultaneously bound allosteric ligands. *ACS Med Chem Lett*. 2020;11(12):2484-2490.
172. Platania CBM, Bucolo C. Molecular dynamics simulation techniques as tools in drug discovery and pharmacology: a focus on allosteric drugs. *Methods Mol Biol*. 2021;2253:245-254.
173. Nguyen D, Lin LY, Zhou JO, et al. Identification and characterization of a B-Raf kinase alpha-helix critical for the activity of MEK kinase in MAPK signaling. *Biochemistry*. 2020;59(50):4755-4765.
174. Ni D, Liu N, Sheng C. Allosteric modulators of protein-protein interactions (PPIs). *Adv Exp Med Biol*. 2019;1163:313-334.
175. Han B, Salituro FG, Blanco MJ. Impact of allosteric modulation in drug discovery: innovation in emerging chemical modalities. *ACS Med Chem Lett*. 2020;11(10):1810-1819.
176. Krojer T, Fraser JS, von Delft F. Discovery of allosteric binding sites by crystallographic fragment screening. *Curr Opin Struct Biol*. 2020;65:209-216.
177. Sun Y, Meyers BA, Czako B, et al. Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib. *Cancer Res*. 2020;80(21):4840-4853.
178. Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. *Science*. 1991;254(5038):1598-1603.
179. Nussinov R, Wolynes PG. A second molecular biology revolution? The energy landscapes of biomolecular function. *Phys Chem Chem Phys*. 2014;16(14):6321-6322.
180. Chen J, Schafer NP, Wolynes PG, Clementi C. Localizing frustration in proteins using all-atom energy functions. *J Phys Chem B*. 2019;123(21):4497-4504.
181. Medina E, D RL, Sanabria H. Unraveling protein's structural dynamics: from configurational dynamics to ensemble switching guides functional mesoscale assemblies. *Curr Opin Struct Biol*. 2020;66:129-138.
182. Hegler JA, Weinkam P, Wolynes PG. The spectrum of biomolecular states and motions. *HFSP J*. 2008;2(6):307-313.
183. Oliveberg M, Wolynes PG. The experimental survey of protein-folding energy landscapes. *Q Rev Biophys*. 2005;38(3):245-288.
184. Sutto L, Latzer J, Hegler JA, Ferreiro DU, Wolynes PG. Consequences of localized frustration for the folding mechanism of the IM7 protein. *Proc Natl Acad Sci USA*. 2007;104(50):19825-19830.
185. Byun JA, VanSchouwen B, Akimoto M, Melacini G. Allosteric inhibition explained through conformational ensembles sampling distinct “mixed” states. *Comput Struct Biotechnol J*. 2020;18:3803-3818.
186. Weinkam P, Zimmermann J, Romesberg FE, Wolynes PG. The folding energy landscape and free energy excitations of cytochrome c. *Acc Chem Res*. 2010;43(5):652-660.
187. Ma B, Kumar S, Tsai CJ, Nussinov R. Folding funnels and binding mechanisms. *Protein Eng*. 1999;12(9):713-720.
188. Onuchic JN, Luthey-Schulten Z, Wolynes PG. Theory of protein folding: the energy landscape perspective. *Annu Rev Phys Chem*. 1997;48:545-600.
189. Tsai CJ, Kumar S, Ma B, Nussinov R. Folding funnels, binding funnels, and protein function. *Protein Sci*. 1999;8(6):1181-1190.
190. Tsai CJ, Ma B, Nussinov R. Folding and binding cascades: shifts in energy landscapes. *Proc Natl Acad Sci USA*. 1999;96(18):9970-9972.
191. Wolynes PG. Folding funnels and energy landscapes of larger proteins within the capillarity approximation. *Proc Natl Acad Sci U S A*. 1997;94(12):6170-6175.
192. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: dynamic landscapes and population shifts. *Protein Sci*. 2000;9(1):10-19.
193. Gunasekaran K, Ma B, Nussinov R. Is allostery an intrinsic property of all dynamic proteins? *Proteins*. 2004;57(3):433-443.
194. Nussinov R, Tsai CJ, Xin F, Radivojac P. Allosteric post-translational modification codes. *Trends Biochem Sci*. 2012;37(10):447-455.
195. Nussinov R, Tsai CJ. Allostery without a conformational change? Revisiting the paradigm. *Curr Opin Struct Biol*. 2015;30:17-24.
196. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. *Nat Chem Biol*. 2009;5(11):789-796.
197. del Sol A, Tsai CJ, Ma B, Nussinov R. The origin of allosteric functional modulation: multiple pre-existing pathways. *Structure*. 2009;17(8):1042-1050.
198. Onuchic JN, Wolynes PG. Theory of protein folding. *Curr Opin Struct Biol*. 2004;14(1):70-75.
199. Shoemaker BA, Wang J, Wolynes PG. Exploring structures in protein folding funnels with free energy functionals: the transition state ensemble. *J Mol Biol*. 1999;287(3):675-694.

200. Marx DC, Leblanc MJ, Plummer AM, Krueger S, Fleming KG. Domain interactions determine the conformational ensemble of the periplasmic chaperone SurA. *Protein Sci*. 2020;29(10):2043-2053.
201. Shen T, Zong C, Hamelberg D, McCammon JA, Wolynes PG. The folding energy landscape and phosphorylation: modeling the conformational switch of the NFAT regulatory domain. *FASEB J*. 2005;19(11):1389-1395.
202. Ezerski JC, Cheung MS. CATS: a tool for clustering the ensemble of intrinsically disordered peptides on a flat energy landscape. *J Phys Chem B*. 2018;122(49):11807-11816.
203. Nussinov R, Tsai CJ, Ma B. The underappreciated role of allostery in the cellular network. *Annu Rev Biophys*. 2013;42:169-189.
204. Gigli L, Andrałojć W, Dalaloyan A, et al. Assessing protein conformational landscapes: integration of DEER data in Maximum Occurrence analysis. *Phys Chem Chem Phys*. 2018;20(43):27429-27438.
205. Nussinov R, Ma B, Tsai CJ. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. *Biochim Biophys Acta*. 2013;1834(5):820-829.
206. Thompson MK, Ehlinger AC, Chazin WJ. Analysis of functional dynamics of modular multidomain proteins by SAXS and NMR. *Methods Enzymol*. 2017;592:49-76.
207. Allison JR. Computational methods for exploring protein conformations. *Biochem Soc Trans*. 2020;48(4):1707-1724.
208. Starovoytov ON, Zhang P, Cieplak P, Cheung MS. Induced polarization restricts the conformational distribution of a light-harvesting molecular triad in the ground state. *Phys Chem Chem Phys*. 2017;19(34):22969-22980.
209. Fuxreiter M. Fuzzy protein theory for disordered proteins. *Biochem Soc Trans*. 2020;48:2557-2564.
210. Zsolyomi F, Ambrus V, Fuxreiter M. Patterns of dynamics comprise a conserved evolutionary trait. *J Mol Biol*. 2020;432(2):497-507.
211. Nussinov R, Wang G, Tsai CJ, et al. Calmodulin and PI3K Signaling in KRAS cancers. *Trends Cancer*. 2017;3(3):214-224.
212. Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O. The key role of calmodulin in KRAS-Driven Adenocarcinomas. *Mol Cancer Res*. 2015;13(9):1265-1273.
213. Chu N, Viennet T, Bae H, et al. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling. *eLife*. 2020;9.
214. Yudushkin I. Control of Akt activity and substrate phosphorylation in cells. *IUBMB Life*. 2020;72(6):1115-1125.
215. Siess KM, Leonard TA. Lipid-dependent Akt-ivity: where, when, and how. *Biochem Soc Trans*. 2019;47(3):897-908.
216. Liu L, Fan S, Li W, Tao W, Shi T, Zhao YL. Theoretical investigation of the structural characteristics in the active state of Akt1 kinase. *J Chem Inf Model*. 2019;59(1):316-325.
217. Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK network as a therapeutic target in human cancer. *Mol Cancer Res*. 2021;19(3):361-374.
218. Gerosa L, Chidley C, Fröhlich F, et al. Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells. *Cell Syst*. 2020;11(5):478-494.
219. Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. *Nat Struct Mol Biol*. 2010;17(6):666-672.
220. Otten R, Pádua RAP, Bunzel HA, et al. How directed evolution reshapes the energy landscape in an enzyme to boost catalysis. *Science*. 2020;370(6523):1442-1446.
221. Nussinov R, Tsai CJ, Jang H. Oncogenic Ras isoforms signaling specificity at the membrane. *Cancer Res*. 2018;78(3):593-602.
222. Maria-Solano MA, Serrano-Hervas E, Romero-Rivera A, Iglesias-Fernandez J, Osuna S. Role of conformational dynamics in the evolution of novel enzyme function. *Chem Commun (Camb)*. 2018;54(50):6622-6634.
223. Sharma R, Demény M, Ambrus V, et al. Specific and fuzzy interactions cooperate in modulating protein half-life. *J Mol Biol*. 2019;431(8):1700-1707.
224. Ma B, Shatsky M, Wolfson HJ, Nussinov R. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. *Protein Sci*. 2002;11(2):184-197.
225. Nussinov R, Tsai CJ. Free energy diagrams for protein function. *Chem Biol*. 2014;21(3):311-318.
226. Kulkarni P, Solomon TL, He Y, Chen Y, Bryan PN, Orban J. Structural metamorphism and polymorphism in proteins on the brink of thermodynamic stability. *Protein Sci*. 2018;27(9):1557-1567.
227. Csermely P, Palotai R, Nussinov R. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. *Trends Biochem Sci*. 2010;35(10):539-546.
228. Weikl TR, von Deuster C. Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. *Proteins*. 2009;75(1):104-110.
229. Kar G, Keskin O, Gursoy A, Nussinov R. Allostery and population shift in drug discovery. *Curr Opin Pharmacol*. 2010;10(6):715-722.
230. McClendon CL, Friedland G, Mobley DL, Amirkhani H, Jacobson MP. Quantifying correlations between allosteric sites in thermodynamic Ensembles. *J Chem Theory Comput*. 2009;5(9):2486-2502.

231. Gardino AK, Villali J, Kivenson A, et al. Transient non-native hydrogen bonds promote activation of a signaling protein. *Cell*. 2009;139(6):1109-1118.
232. Tsai CJ, Nussinov R. The molecular basis of targeting protein kinases in cancer therapeutics. *Semin Cancer Biol*. 2013; 23(4):235-242.
233. Steklov M, Pandolfi S, Baietti MF, et al. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. *Science*. 2018;362(6419):1177-1182.
234. Pádua RAP, Sun Y, Marko I, et al. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. *Nat Commun*. 2018;9(1):4507.
235. Muratcioglu S, Aydin C, Odabasi E, et al. Oncogenic K-Ras4B dimerization enhances downstream mitogen-activated protein kinase signaling. *J Mol Biol*. 2020;432(4):1199-1215.
236. Cope NJ, Novak B, Liu Z, et al. Analyses of the oncogenic BRAF(D594G) variant reveal a kinase-independent function of BRAF in activating MAPK signaling. *J Biol Chem*. 2020;295(8):2407-2420.
237. Zhou ZW, Ambrogio C, Bera AK, et al. KRAS(Q61H) preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. *Cancer Res*. 2020;80(17):3719-3731.
238. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. *Mol Cancer Res*. 2015;13(9):1325-1335.
239. Tsai CJ, Nussinov R. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? *Phys Chem Chem Phys*. 2014;16(14):6332-6341.
240. Leontiadou H, Galdadas I, Athanasiou C, Cournia Z. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. *Sci Rep*. 2018;8(1):15544.
241. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature*. 2017;548(7666):234-238.
242. Cotto-Rios XM, Agianian B, Gitego N, et al. Inhibitors of BRAF dimers using an allosteric site. *Nat Commun*. 2020; 11(1):4370.
243. Liao TJ, Jang H, Nussinov R, Fushman D. High-affinity interactions of the nSH3/cSH3 domains of Grb2 with the C-terminal proline-rich domain of SOS1. *J Am Chem Soc*. 2020;142(7):3401-3411.
244. Liao TJ, Jang H, Fushman D, Nussinov R. SOS1 interacts with Grb2 through regions that induce closed nSH3 conformations. *J Chem Phys*. 2020;153(4):045106.
245. Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J, Samelson LE. Role of Grb2 in EGF-stimulated EGFR internalization. *J Cell Sci*. 2002;115(Pt 9):1791-1802.
246. Lu S, Jang H, Muratcioglu S, et al. Ras conformational Ensembles, allostery, and signaling. *Chem Rev*. 2016;116(11): 6607-6665.
247. Mayer BJ. The discovery of modular binding domains: building blocks of cell signalling. *Nat Rev Mol Cell Biol*. 2015; 16(11):691-698.
248. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. *Genes Cancer*. 2011;2(3):344-358.
249. Nussinov R, Tsai CJ, Mattos C. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways. *Trends Mol Med*. 2013;19(11):695-704.
250. Martin-Garcia F, Mendieta-Moreno JI, Lopez-Vinas E, Gomez-Puertas P, Mendieta J. The role of Gln61 in HRas GTP hydrolysis: a quantum mechanics/molecular mechanics study. *Biophys J*. 2012;102(1):152-157.
251. Cao S, Chung S, Kim S, Li Z, Manor D, Buck M. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function. *J Biol Chem*. 2019;294(17):7068-7084.
252. Chavan TS, Muratcioglu S, Marszalek R, et al. Plasma membrane regulates Ras signaling networks. *Cell Logist*. 2015; 5(4):e1136374.
253. Jang H, Banerjee A, Chavan TS, et al. The higher level of complexity of K-Ras4B activation at the membrane. *FASEB J*. 2016;30(4):1643-1655.
254. Jang H, Zhang M, Nussinov R. The quaternary assembly of KRas4B with Raf-1 at the membrane. *Comput Struct Biotechnol J*. 2020;18:737-748.
255. Neale C, Garcia AE. The plasma membrane as a competitive inhibitor and positive allosteric modulator of KRas4B signaling. *Biophys J*. 2020;118(5):1129-1141.
256. Prakash P, Gorfe AA. Probing the conformational and energy landscapes of KRAS membrane orientation. *J Phys Chem B*. 2019;123(41):8644-8652.
257. Prakash P, Litwin D, Liang H, et al. Dynamics of membrane-bound G12V-KRAS from simulations and single-molecule FRET in native nanodiscs. *Biophys J*. 2020;118(2):532.
258. Cruz-Migoni A, Canning P, Quevedo CE, et al. Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. *Proc Natl Acad Sci U S A*. 2019;116(7):2545-2550.
259. Sun Q, Burke JP, Phan J, et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. *Angew Chem Int Ed Engl*. 2012;51(25):6140-6143.

260. Tran TH, Alexander P, Dharmaiah S, et al. The small molecule BI-2852 induces a nonfunctional dimer of KRAS. *Proc Natl Acad Sci U S A*. 2020;117(7):3363-3364.
261. Bergner A, Cockcroft X, Fischer G, et al. KRAS binders hidden in nature. *Chemistry*. 2019;25(52):12037-12041.
262. Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R. Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers. *Biochem J*. 2016;473(12):1719-1732.
263. Yan C, Liu D, Li L, et al. Discovery and characterization of small molecules that target the GTPase Ral. *Nature*. 2014; 515(7527):443-447.
264. Mahoney SJ, Narayan S, Molz L, et al. A small molecule inhibitor of Rheb selectively targets mTORC1 signaling. *Nat Commun*. 2018;9(1):548.
265. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov*. 2014;13(2): 140-156.
266. Zhang M, Jang H, Gaponenko V, Nussinov R. Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains. *Biophys J*. 2017;113(9):1956-1967.
267. Joyal JL, Burks DJ, Pons S, et al. Calmodulin activates phosphatidylinositol 3-kinase. *J Biol Chem*. 1997;272(45): 28183-28186.
268. Nolte RT, Eck MJ, Schlessinger J, Shoelson SE, Harrison SC. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. *Nat Struct Biol*. 1996;3(4):364-374.
269. Pauptit RA, Dennis CA, Derbyshire DJ, et al. NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex. *Acta Crystallogr D Biol Crystallogr*. 2001;57(Pt 10):1397-1404.
270. Yu J, Wjasow C, Backer JM. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. *J Biol Chem*. 1998;273(46):30199-30203.
271. Cournia Z, Allen BK, Beuming T, Pearlman DA, Radak BK, Sherman W. Rigorous free energy simulations in virtual screening. *J Chem Inf Model*. 2020;60(9):4153-4169.
272. Cournia Z, Allen B, Sherman W. Relative binding free energy calculations in drug discovery: recent advances and practical considerations. *J Chem Inf Model*. 2017;57(12):2911-2937.
273. Chakrabarti M, Gabelli SB, Amzel LM. Allosteric activation of PI3Kα results in dynamic access to catalytically competent conformations. *Structure*. 2020;28(4):465-474.
274. Zhang M, Li Z, Wang G, et al. Calmodulin (CaM) activates PI3Kα by targeting the "Soft" CaM-binding motifs in both the nSH2 and cSH2 Domains of p85α. *J Phys Chem B*. 2018;122(49):11137-11146.
275. Pirali T, Ciraolo E, Aprile S, et al. Identification of a potent phosphoinositide 3-kinase pan inhibitor displaying a strategic carboxylic acid group and development of its prodrugs. *ChemMedChem*. 2017;12(18):1542-1554.
276. Feng H, Zhang Y, Bos PH, Chambers JM, Dupont MM, Stockwell BR. K-Ras(G12D) has a potential allosteric small molecule binding site. *Biochemistry*. 2019;58(21):2542-2554.
277. Liau NPD, Wendorff TJ, Quinn JG, et al. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. *Nat Struct Mol Biol*. 2020;27(2):134-141.
278. Jordan EJ, Patil K, Suresh K, et al. Computational algorithms for in silico profiling of activating mutations in cancer. *Cell Mol Life Sci*. 2019;76(14):2663-2679.
279. McClendon CL, Kornev AP, Gilson MK, Taylor SS. Dynamic architecture of a protein kinase. *Proc Natl Acad Sci USA*. 2014;111(43):E4623-E4631.
280. Maloney RC, Zhang M, Jang H, Nussinov R. The mechanism of activation of monomeric B-Raf V600E. *Comput Struct Biotechnol J*. 2021;19:3349-3363.
281. Röring M, Herr R, Fiala GJ, et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. *EMBO J*. 2012;31(11):2629-2647.
282. Yuan J, Ng WH, Lam PYP, et al. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants. *Oncogene*. 2018;37(43):5719-5734.
283. Wise JF, Lawrence MS. Huge whole-genome study of human metastatic cancers. *Nature*. 2019;575(7781):60-61.
284. Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature*. 2019;575(7781):210-216.
285. Nussinov R, Tsai CJ, Jang H. Are parallel proliferation pathways redundant? *Trends Biochem Sci*. 2020;45(7):554-563.
286. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science*. 2014;343(6167):189-193.
287. Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. *Cell*. 2018; 173(2):321-337.
288. Consortium APG. AACR Project GENIE: powering precision medicine through an international consortium. *Cancer Discov*. 2017;7(8):818-831.
289. Barbee RW, Trippodo NC. The contribution of atrial natriuretic factor to acute volume natriuresis in rats. *Am J Physiol*. 1987;253(6 Pt 2):F1129-F1135.

290. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2(5):401-404.
291. van der Meer D, Barthorpe S, Yang W, et al. Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models. *Nucleic Acids Res*. 2019;47(D1):D923-D929.
292. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res*. 2013;41(Database issue):D955-D961.
293. Liu X, Lu S, Song K, et al. Unraveling allosteric landscapes of allosterome with ASD. *Nucleic Acids Res*. 2020;48(D1):D394-D401.
294. Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med*. 2015;21(11):1318-1325.
295. Cheng F, Zhao J, Wang Y, et al. Comprehensive characterization of protein-protein interactions perturbed by disease mutations. *Nat Genet*. 2021;53(3):342-353.
296. Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. *Nat Rev Genet*. 2019;20(4):207-220.
297. Espiritu D, Gribkova AK, Gupta S, Shaytan AK, Panchenko AR. Molecular mechanisms of oncogenesis through the lens of nucleosomes and histones. *J Phys Chem B*. 2021;125:3963-3976.
298. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med*. 2005;353(20):2135-2147.
299. Zawel L. P3Kα: a driver of tumor metastasis? *Oncotarget*. 2010;1(5):315-316.
300. Schmidt-Kittler O, Zhu J, Yang J, et al. PI3Kα inhibitors that inhibit metastasis. *Oncotarget*. 2010;1(5):339-348.
301. Tan B, Anaka M, Deb S, et al. FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. *Oncotarget*. 2014;5(1):264-276.
302. Li Z, Wang Y, Qiu J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. *Oncotarget*. 2013;4(12):2532-2549.
303. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. *J Biol Chem*. 1996;271(38):23512-23519.
304. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. *Oncogene*. 2010;29(41):5545-5555.
305. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). *Nature*. 2011;480(7377):387-390.
306. Trapnell C. Defining cell types and states with single-cell genomics. *Genome Res*. 2015;25(10):1491-1498.
307. Hsiung CC, Morrissey CS, Udugama M, et al. Genome accessibility is widely preserved and locally modulated during mitosis. *Genome Res*. 2015;25(2):213-225.
308. Haigis KM, Cichowski K, Elledge SJ. Tissue-specificity in cancer: The rule, not the exception. *Science*. 2019;363(6432):1150-1151.
309. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res*. 2012;72(10):2457-2467.
310. Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. *J Cell Sci*. 2016;129(7):1287-1292.
311. Haigis KM. KRAS alleles: the devil is in the detail. *Trends Cancer*. 2017;3(10):686-697.
312. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. *Nucleic Acids Res*. 1988;16(16):7773-7782.
313. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell*. 1988;53(4):549-554.
314. Post JB, Roodhart JML, Snippert HJG. Colorectal cancer modeling with organoids: discriminating between oncogenic RAS and BRAF variants. *Trends Cancer*. 2020;6(2):111-129.
315. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. *Nat Genet*. 2008;40(5):600-608.
316. Li Q, Haigis KM, McDaniel A, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. *Blood*. 2011;117(6):2022-2032.
317. Janssen KP, el-Marjou F, Pinto D, et al. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. *Gastroenterology*. 2002;123(2):492-504.
318. Krøigård AB, Larsen MJ, Lænkholm AV, et al. Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. *PLoS One*. 2018;13(1):e0189887.
319. Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. *Nat Genet*. 2019;51(7):1113-1122.

320. Sack LM, Davoli T, Li MZ, et al. Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns. *Cell*. 2018;173(2):499-514.
321. Nussinov R, Jang H, Zhang M, Tsai CJ, Sablina AA. The mystery of Rap1 suppression of oncogenic Ras. *Trends Cancer*. 2020;6(5):369-379.
322. Mayran A, Drouin J. Pioneer transcription factors shape the epigenetic landscape. *J Biol Chem*. 2018;293(36): 13795-13804.
323. Nussinov R, Jang H, Nir G, Tsai CJ, Cheng F. A new precision medicine initiative at the dawn of exascale computing. *Signal Transduct Target Ther*. 2021;6(1):3.
324. Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects. *Cancer Manag Res*. 2020;12:2731-2742.
325. Ludwig LS, Lareau CA, Bao EL, et al. Transcriptional states and chromatin accessibility underlying human erythropoiesis. *Cell Rep*. 2019;27(11):3228-3240.
326. Aughey GN, Estacio Gomez A, Thomson J, Yin H, Southall TD. CATaDa reveals global remodelling of chromatin accessibility during stem cell differentiation in vivo. *eLife*. 2018;7.
327. Chung CY, Ma Z, Dravis C, et al. Single-cell chromatin analysis of mammary gland development reveals cell-state transcriptional regulators and lineage relationships. *Cell Rep*. 2019;29(2):495-510.
328. Zhang S, Moy W, Zhang H, et al. Open chromatin dynamics reveals stage-specific transcriptional networks in hiPSC-based neurodevelopmental model. *Stem Cell Res*. 2018;29:88-98.
329. Kazakevych J, Sayols S, Messner B, Krienke C, Soshnikova N. Dynamic changes in chromatin states during specification and differentiation of adult intestinal stem cells. *Nucleic Acids Res*. 2017;45(10):5770-5784.
330. Arda HE, Tsai J, Rosli YR, et al. A chromatin basis for cell lineage and disease risk in the human pancreas. *Cell Syst*. 2018;7(3):310-322.
331. Roy S, Sridharan R. Chromatin module inference on cellular trajectories identifies key transition points and poised epigenetic states in diverse developmental processes. *Genome Res*. 2017;27(7):1250-1262.
332. Mallm JP, Iskar M, Ishaque N, et al. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. *Mol Syst Biol*. 2019;15(5):e8339.
333. Ma Y, McKay DJ, Buttitta L. Changes in chromatin accessibility ensure robust cell cycle exit in terminally differentiated cells. *PLoS Biol*. 2019;17(9):e3000378.
334. Schoenfelder S, Mifsud B, Senner CE, et al. Divergent wiring of repressive and active chromatin interactions between mouse embryonic and trophoblast lineages. *Nat Commun*. 2018;9(1):4189.
335. Zhao Y, Zheng D, Cvekl A. Profiling of chromatin accessibility and identification of general cis-regulatory mechanisms that control two ocular lens differentiation pathways. *Epigenetics Chromatin*. 2019;12(1):27.
336. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. *Annu Rev Pathol*. 2013; 8:277-302.
337. Eisfeld AK, Schwind S, Hoag KW, et al. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. *Proc Natl Acad Sci USA*. 2014;111(11):4179-4184.
338. National Cancer Institute. Drugs Approved for Breast Cancer. 2021; https://www.cancer.gov/about-cancer/treatment/drugs/breast
339. Zhou Y, Zhao J, Fang J, et al. My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. *Genome Biol*. 2021;22(1):53.

AUTHOR BIOGRAPHIES

Ruth Nussinov pioneered the "conformational selection and population shift" (1999) as an alternative to the "induced fit" textbook model to explain the molecular mechanism of recognition and posited that population shift underlies allosteric regulation. She extended this pre-existing ensemble model to catalysis (2000), and oncogenic activation, contributing to extraordinary advancements in understanding structure and function. Nussinov received her PhD in 1977 from Rutgers University and did post-doctoral work in the Structural Chemistry Department of the Weizmann Institute. Subsequently, she was at the Chemistry Department at Berkeley, the Biochemistry Department at Harvard, and a visiting scientist at the NIH. In 1984 she joined the Department of Human Genetics, at the Medical School at Tel Aviv University. In 1985, she accepted a concurrent position at the National Cancer Institute of the NIH, Leidos Biomedical Research, where she is a Senior Principal Scientist and Principle Investigator heading the Computational Structural Biology Section at the NCI. She has authored over 650 scientific papers. She is the Editor-in-Chief of *Current Opinion in Structural*

Biology, was the Editor-in-Chief of *PLoS Computational Biology*, is currently the Editor-in-Chief of *Current Opinion in Structural Biology*, and Associate Editor and on the Editorial Boards of a number of journals. She is a frequent speaker in Domestic and International meetings, symposia, and academic institutions, won multiple awards and elected fellow of several societies, and has been twice *a highly cited researcher*. Her National Cancer Institute website gives further details. https://ccr.cancer.gov/ruth-nussinov.

Mingzhen Zhang is a computational scientist in Computational Structural Biology Section at Frederick National Laboratory for Cancer Research in the Laboratory of Cancer Immunometabolism, National Cancer Institute (NCI), MD, USA. His research focuses on the activation mechanism of key oncogenic proteins in Ras signaling pathways. He uses computational tools to uncover the detailed high-resolution activation mechanisms of PI3K and Raf, the main downstream effectors of Ras, and explore the structural principles for cancer drug discovery.

Ryan Maloney is a postdoctoral research fellow and Cancer Research Training Award recipient in the Laboratory of Cancer Immunometabolism at National Cancer Institute, Frederick, MD. He completed his bachelor's degree and graduated with distinction from the University of Illinois in 2008. His Ph.D. thesis, "Computer Simulations of Binary Mixtures of Colloidal Particles" was completed in 2020 from the Department of Chemical and Biomolecular Engineering at North Carolina State University. Building off his skills in writing code to perform molecular dynamics simulations, he has transitioned from researching colloidal systems to investigating oncogenic proteins. His research interests involve using molecular dynamics approaches to understand the mechanism of activation of proteins in the MAPK pathway.

Chung-Jung Tsai is in the Laboratory of Cancer Immunometabolism, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD. Dr Tsai received his PhD in chemistry from the University of Pittsburgh in 1992, followed by a brief period as a Postdoctoral Fellow there with Professor K. D. Jordan. Since then he has been at National Cancer Institute. Broadly, Dr Tsai's research interests focus primarily on the study of protein folding, binding, function, and dysfunction. He has published over 130 papers in the fields of computational chemistry, physics, and biology.

Bengi Ruken Yavuz is PhD candidate in Medical Informatics Department at Middle East Technical University, Ankara. Her study employs computational methods to integrate and analyze multi-omics cancer data sets from a precision oncology perspective to reveal actionable knowledge. She is particularly interested in identifying latent driver mutations among passenger mutations using pan-cancer data sets and computationally evaluating the effects of cooperatively acting mutations on tumor growth, drug response, and other clinical factors. She completed her Master's and Bachelor's degrees in Mathematics at Bilkent University and Middle East Technical University, respectively, in Ankara, Turkey.

Nurcan Tuncbag is an associate professor at Koç University jointly in the Department of Chemical and Biological Engineering and School of Medicine. She received her B.S. degree in Chemical Engineering from Istanbul Technical University (iTÜ), and her MS and PhD degrees from Koç University Computational Sciences and Engineering department. She did her post-doctoral research in Massachusetts Institute of Technology (MIT) Biological Engineering Department between 2010 and 2014. She was a faculty member at Middle East Technical University (ODTÜ) between 2014 and 2021. Her work in computational systems biology and bioinformatics has been recognized by several young scientist awards of national academies and organizations, including TUBA-GEBIP, BA-BAGEP. She was selected as one of 15 International Rising Talents by UNESCO-L'Oreal Foundation in 2019. She has been a member of the Global Young Academy since 2020. Her research interests are computational systems biology, bioinformatics, network-based medicine, network modeling, multi-omic data integration, single-cell and bulk omic data analysis, and discovery of latent cancer driver mutations.

She continues her research on how the interaction networks between proteins and genes are altered in diseases by using multi-omic data integration and network modeling techniques.

Hyunbum Jang is a senior scientist at Frederick National Laboratory for Cancer Research in the Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD. He earned his PhD in condensed matter physics studying thin magnetic films with the competing surface fields by performing a series of Monte Carlo (MC) simulations of the Heisenberg spin systems with anisotropy. In his early career, his research focused on the thermodynamic and kinetic properties of isolated β-sheet proteins and β-sheet complex using the discontinuous molecular dynamics (DMD) technique. Moving towards more complex biomolecular systems, his research focused on the membrane proteins using all-atom molecular dynamics (MD) simulations with the CHARMM and NAMD programs. His interests involved a wide range of membrane systems from a membrane-bound small peptide to a large complex of ion channels in various bilayer systems. He developed the force field parameters and topologies of non-standard biomolecules for the MD simulations with CHARMM. Currently, his research focuses on the biological agents that are responsible for oncogenic signaling through the MAPK and PI3K/AKT pathways. He is a member of the American Association for Cancer Research and the Biophysical Society.

How to cite this article: Nussinov R, Zhang M, Maloney R, et al. Mechanism of activation and the rewired network: new drug design concepts. *Med Res Rev*. 2021;1-30. https://doi.org/10.1002/med.21863